CURRICULUM VITAE
Gilbert S. Omenn, M.D., Ph.D.
The University of Michigan
1150 W. Medical Center Dr., A510 MSRB 1, Ann Arbor, Michigan 48109-0656
(734) 763-7583 Fax: (734) 647-8148 gomenn@umich.edu
Personal
Born:
Wife:
Children:
Chester, Pennsylvania, August 30, 1941
Martha Darling
Rachel, Jason, and David
Education
1958
1961
1965
1972
Chester High School, Chester, PA
Princeton University, Princeton, NJ, A.B., summa cum laude
Harvard Medical School, Boston, MA, M.D., magna cum laude
University of Washington, Seattle, WA, Ph.D. (genetics)
Positions and Professional Training
1960-summer Research Fellow, Woods Hole Oceanographic Institution, Woods Hole, MA
1961-summer Research Fellow, Brookhaven National Laboratory, Upton, L.I., NY
1962-summer Research Fellow, Weizmann Institute of Science, Rehovot, Israel
1962-65
Harvard Medical School, Boston, MA, M.D. Thesis Program
1965-67
Intern, Assistant Resident in Medicine, Massachusetts General Hospital, Boston, MA
1966-67
Teaching Fellow in Medicine, Harvard University, Boston, MA
1967-69
Research Associate, National Institute of Arthritis and Metabolic Diseases, NIH, Bethesda, MD
1969-71
Fellow, Division of Medical Genetics, University of Washington, Seattle, WA
1971-74
Assistant Professor of Medicine (Medical Genetics), University of Washington, Seattle, WA
1971-97
Attending Staff, University Hospital, Harborview Medical Center, Veterans Administration
Hospital, Providence Hospital; Consulting Staff, Children's Hospital and Medical Center, Seattle
1973-74
White House Fellow/Special Assistant to Chair, Atomic Energy Commission, Washington, DC
1974-79
Associate Professor of Medicine (Medical Genetics), University of Washington, Seattle, WA
1975-77
Director, Robert Wood Johnson Clinical Scholars Program at U of Washington, Seattle, WA
1976-77
Investigator, Howard Hughes Medical Institute
1977-81
Assistant Director (1977-78), Associate Director (1978-80) for Human Resources and Social
and Economic Services, Office of Science and Technology Policy; Associate Director for Human
Resources, Veterans, and Labor, OMB (1980-81),Executive Office of the President, Wash, DC
1979-97
Professor of Medicine (Medical Genetics), University of Washington, Seattle, WA
1981-spring Visiting Senior Fellow, Woodrow Wilson School of Public and International Affairs, Princeton
University, Princeton, NJ
1981-82
Science and Public Policy Fellow, Brookings Institution, Washington, DC
1981Professor of Environmental Health, University of Washington, Seattle, WA; Affiliate Prof 9/97-1982-83
Chair, Department of Environmental Health, University of Washington, Seattle, WA
1982-97
Dean, School of Public Health and Community Medicine, University of Washington, Seattle, WA
1983Member (joint), Fred Hutchinson Cancer Research Center, Seattle, WA (affiliate, 1997--)
1997-2002
Executive Vice President for Medical Affairs, CEO of University of Michigan Health System,
Ann Arbor, MI
1997Professor of Internal Medicine, Human Genetics and Public Health, University of Michigan
Fellowships, Awards, Honors
1969-71
U.S. Public Health Service Special Fellow
1971-72
National Genetics Foundation Fellow
1972-76
Research Career Development Award, National Institute of General Medical Sciences
1973-74
White House Fellow, Atomic Energy Commission, Germantown, MD
1978
Fellow, American College of Physicians
1978
Member, Institute of Medicine, National Academy of Sciences
1981
1985
1991
1991
1992
2001
2001
Fellow, Hastings Center Institute of Society, Ethics and Life Sciences
Fellow, Collegium Ramazzini, Carpi, Italy
Fellow, American Association for the Advancement of Science
Member, National Academy of Social Insurance
Member, Western Association of Physicians
Member, American Academy of Arts and Sciences
Member, Association of American Physicians
Licensure to Practice
States of Massachusetts, Washington, Michigan
Board of Internal Medicine-Certified Part 1 (1970), Part 2 (1972)
Specialty Board of Medical Genetics-Clinical Genetics (1982)
Professional Organizations
Association of American Physicians, American Academy of Arts & Sciences, Alpha Omega Alpha, American
Association for Advancement of the Humanities, American Association for the Advancement of Science, American
Society of Human Genetics, Boylston Medical Society, Phi Beta Kappa, Physicians for Human Rights, Sigma Xi,
White House Fellows Association
Current Professional Activities
Member, National Academy of Sciences/National Research Council (NAS/NRC) Report Review Committee; NAS
Planning Committee for Science, Technology, and Economic Policy (STEP) Board on Medical Innovation, 2000--;
NRC Committee on Organization of the NIH, 2002--; co-Chair, National Advisory Committee, Robert Wood
Johnson Foundation/WK Kellogg Foundation Program, Turning Point: Collaborating for a New Century in Public
Health, 1997--; Member, Scientific Advisory Committee, W K Kellogg Foundation Minority Fellowships in Health
Policy Research, 1998--; Environmental Protection Agency Science Advisory Board, 1999--; American Cancer
Society Advisory Group on Cancer and the Environment, 1999--; Assn of Academic Health Centers Division of
Global Health Advisory Committee, 1999--; Human Proteome Organization (HUPO), Council member, 2001--.
Member, Boards of Directors: Rohm and Haas Company, 1987--; Amgen, Inc 1987--; Population Services
International (PSI), 1988--; Health and Environmental Science Institute (HESI) of the International Life Sciences
Institute (ILSI)1989--; Partnership for Prevention, 1991--; Fred Hutchinson Cancer Research Center (Senior
Council), 1995--, CNA Corp, 2003--; American Association for the Advancement of Science, 2004--.
Member, Scientific Advisory Committees: Motorola, 1998--; 3M 1998--; Divergence 2000--; Novodynamics Inc
2001--; Acumen Sciences 2002--; Immune Response Corp, 2002--; Pacific NW National Laboratory, 2003--.
Publications: Published Papers: Experimental and Clinical Research (142); Review and Policy Papers (234)
Books (17), Book Reviews (44); Published Abstracts (133)
Editor: Annual Review of Public Health, 1990-96; Oxford Textbook of Public Health, 1993-97
Co-Editor: Western Journal of Medicine, special 1995 issue on Care of the Dying Patient
Associate Editor: American Journal of Human Genetics, 1972-75, Cancer Research, 1988-96
Guest Editor: Clinics in Geriatric Medicine, 1991-92
Research Interests: Cancer prevention, proteomics, public health genetics, science-based risk analysis, health policy
Recreational Interests: Family, music, tennis, public policy
Community Boards: United Way of Washtenau County; University Musical Society; Harvard Medical School Alumni
Council (chair, Adv Comm on Medical Education), Communitarian Network (National Council).
Published Papers: Experimental and Clinical Research
1.
Blumer M, Omenn G. Fossil chlorins in a triassic sediment. Nature 1961; 191: 161-162.
2.
Blumer M, Omenn GS. Fossil porphyrins: uncomplexed chlorins in a triassic sediment. Geochim et Cosmochim Acta
1961;25:81-90.
3.
Gill TJ III, Omenn GS. Studies on the helix-coil transition by polarization of fluorescence measurements. J Am Chem
Soc 1965;87:4188-4189.
4.
Omenn GS. Familial reticuloendotheliosis with eosinophilia. N Engl J Med 1965; 273:427-432.
5.
Omenn GS, Gill TJ III. Studies of polypeptide structure by fluorescence techniques. II. The effect of temperature and
viscosity on the polarization of fluorescence of synthetic polypeptide-dye conjugates. J. Biol Chem 1966; 241: 48994906.
6.
Gill TJ III, McLaughlin EM, Omenn GS. Studies of polypeptide structure by fluorescence techniques. III. Interaction
between dye and macromolecule in fluorescent conjugates. Biopolymers 1967; 5: 297-311.
7.
Rapoport AH, Omenn GS. Dermatomyositis and malignant effusion: rare manifestations of carcinoma of the prostate. J
Urol 1968; 100:183-187.
8.
Omenn GS, Anfinsen CB. Solid-phase peptide coupling. J Am Chem Soc 1968; 90:6571-6572.
9.
Omenn GS, Roth SI, Baker WH. Hyperparathyroidism associated with malignant tumors of non-parathyroid origin.
Cancer 1969; 244:1004-1012.
10.
Omenn GS, Cuatrecasas P, Anfinsen CB. Studies of the aromatic circular dichroism of staphylococcal nuclease.
Proc Natl Acad Sci U.S. 1969; 64:923-930.
11.
Copeland RB, Omenn GS. Electrocardiogram changes suggestive of coronary artery disease in pneumothorax: their
reversibility with upright posture. Arch Intern Med 1970; 125:151-153.
12.
Omenn GS. Ectopic polypeptide hormone production by tumors. Ann Intern Med 1970; 72:136-138.
13.
Omenn GS, Ontjes DA, Anfinsen CB. Immunochemistry of staphylococcal nuclease. I. Physical, enzymatic, and
immunological characterization of chemically modified derivatives. Biochemistry 1970; 9:304-312.
14.
Omenn GS, Ontjes DA, Anfinsen CB. Immunochemistry of staphylococcal nuclease. II. Studies of peptide fragments.
Biochemistry 1970; 9:313-321.
15.
Omenn GS, Ontjes DA, Anfinsen CB. Fractionation of antibodies against staphylococcal nuclease on Sepharose
immunoadsorbents. Nature 1970; 225:189-190.
16.
Omenn GS, Fontana A, Anfinsen CB. Modification of the single tryptophan residue of staphylococcal nuclease by a new,
mild oxidizing agent. J Biol Chem 1970; 245:1895-1902.
17.
Omenn GS, Friedman J. Isolation of mutants of Staphylococcus aureus lacking extracellular nuclease activity.
J Bacteriol 1970; 101:921-924.
18.
Omenn GS, Wilkins EW Jr. Hormonal syndromes associated with bronchogenic carcinoma: clues to histological type. J
Thorac Cardiovasc Surg 1970; 59:877-881.
19.
Omenn GS, Dahl LK, Mather GW. Effects of chronic excess salt feeding: demonstration of normal thyroid function in
salt-fed dogs with hyper-cholesterolemia. Proc Soc Exper Biol Med 1970; 135: 380-383.
20.
Parikh I, Omenn GS. Modification of staphylococcal nuclease with nitro-phenylsulfenyl halides. Biochemistry 1971;
10:1173-1177.
21.
Omenn GS. Pancoast syndrome due to metastatic carcinoma from the uterine cervix. Chest 1971;60: 268-270.
22. Omenn GS, Cohen PTW. Electrophoretic methods for differentiating glycolytic enzymes of mouse and human origin. In
Vitro 1971: 7:132-139.
23. Omenn GS, Motulsky AG. A biochemical and genetic approach to alcoholism. In: Seixas FA, Omenn GS, Burk ED,
Eggleston SA, editors. Nature and nurture in alcoholism. Ann NY Acad Sci 1972; 197:16-23. Editorial notes p. 24-25,
66-67, 108-109, 126-128.
24.
Omenn GS, Motulsky AG. Biochemical genetics and the evolution of human behavior. In: Ehrman L, Omenn GS,
Caspari E, editors. Genetics, environment, and behavior: implications for educational policy. New York: Academic
Press, 1972:129-172.
25.
Cohen PTW, Omenn GS. Genetic variation of cytoplasmic and mitochondrial malic enzymes in the monkey Macaca
nemestrina. Biochem Genet 1972; 7:289-301.
26.
Cohen PTW, Omenn GS. Human malic enzyme:high frequency polymorphism of the mitochondrial form. Biochem
Genet 1972; 7:303-311.
27.
Omenn GS. Genetic approaches to the syndrome of minimal brain dysfunction. Seminars in Psychiatry 1973;
5:5-17.
28.
Cohen PTW, Omenn GS, Motulsky AG, Chen SH, Giblett ER. Restricted variation in the glycolytic enzymes of human
brain and erythrocytes. Nature New Biology 1973; 241:229-233.
29.
Grouse L, Omenn GS, McCarthy BJ. Studies of DNA-RNA hybridization of the transcriptional diversity of human brain.
J Neurochem 1973; 20:1063-73.
30.
Omenn GS. Pathobiology of ectopic hormone production by neoplasms in man. Pathobiology Annual 1973; 3:
177-216.
31.
Omenn GS, Figley MM, Graham CB, Heinrichs WL. Prospects for radiographic intrauterine diagnosis--the syndrome of
thrombocytopenia with absent radii. N Engl J Med 1973; 288:777-778.
32.
Schrott HG, Karp L, Omenn GS. Prenatal prediction in myotonic dystrophy: guidelines for genetic counseling. Clin
Genet 1973; 4:38-45.
33.
Caplan R, Cheung S, Omenn GS. Electrophoretic profiles of proteins of human cerebral cortex: population and
developmental characteristics. J Neurochem 1974; 22:517-520.
34.
Omenn GS, Cheung S. Phosphoglycerate mutase isoenzyme marker for tissue differentiation in man. Am J Hum Gen
1974; 26:393-399.
35.
Palmieri GMA, Nordquist RD, Omenn GS. Immunochemical localization of parathyroid hormone in cancer tissue from
patients with ectopic hyperparathyroidism. J Clin Invest 1974; 53:1726-1735.
36.
McGuire L, Omenn GS. Congenital adrenal hyperplasia (adrenogenital syndrome). I. Family studies of IQ. Behav
Genet 1975; 5:165-173.
37.
McGuire L, Ryan KO, Omenn GS. Congenital adrenal hyperplasia (adrenogenital syndrome). II. Cognitive and
behavioral studies. Behav Genet 1975; 5:175-188.
38.
Omenn GS, Hermodson MA. Human phosphoglycerate mutase: isozyme marker for muscle differentiation and for
neoplasia. Proceedings of the Third International Isozyme Conference. Markert CD, Vesell ES, editors. New York:
Academic Press, 1975:1005-1018.
39.
Karp L, Smith DW, Omenn GS, Johnson S, Jones KL. The use of ultrasound in the prenatal exclusion of primary
microcephaly. Gynecol Invest 1974; 5:311-316.
40.
Schrott HG, Omenn GS. Myotonic dystrophy: opportunities for prenatal prediction. Neurology 1975; 25:
789-791.
41.
Bird TD, Omenn GS. Monozygotic twins with Huntington's disease in a family expressing the rigid variant. Neurology
1975; 25:1126-1129.
42.
Omenn GS. Pharmacogenetic aspects of treating behavioral disorders in children with drugs. In: Siva Sankar DV, editor.
Psychopharmacology of childhood. Westbury, NY: PJD Publications, 1976:123-138.
43.
Weber BA, Omenn GS. Auditory and visual evoked responses in children with familial reading disabilities.
J Learn Disabil 1977; 10:153-158.
44.
Hansen KD, Omenn GS. Genetic counseling: the search for the adopted child. J Leg Med 1976; 4:8AA-8FF.
45.
Clark RA, Omenn GS. Anhidrotic ectodermal dysplasia with frequent infections and amyloidosis. West J Med 1977;
126:225-228.
46.
Omenn GS, Hall J, Graham CB, Karp LE. The use of radiographic visualization for prenatal diagnosis. In: Embryology
and Pathogenesis and Prenatal Diagnosis, Birth Defects: Original Article Series XII, No. 3D, 1977:217-229.
47.
Larson EB, Omenn GS. Impact of computed tomography on the care of patients with suspected brain tumor. Med Care
1977; 15:543-551.
48.
Larson EB, Omenn GS, Margolis MT, Loop JW. Impact of computed tomography on utilization of cerebral angiograms.
Am J Roentgenol 1977; 129:1-3.
49.
Omenn GS, Bird TD, Johnsen SD. Serotonin in essential myoclonus. N Engl J Med 1977; 297:454.
50.
Omenn GS, Smith LT. Platelet uptake of serotonin and dopamine in Huntington disease. Neurology 1978; 28:
300-303.
51.
Smith LT, Hanson DR, Omenn GS. Comparisons of serotonin uptake by blood platelets and brain synaptosomes. Brain
Res 1978; 146:400-403.
52.
Omenn GS, Smith LT. A common uptake system for serotonin and dopamine in human platelets. J Clin Invest 1978;
62:235-240.
53.
Omenn GS, Weber BA. Dyslexia: search for phenotypic and genetic heterogeneity. Am J Med Genetics 1978;
1:333-342.
54.
Grouse L, Shrier B, Omenn GS, Nelson P. Measurements of gene expression in tissues of normal and dystrophic mice.
Exp Neurol 1978; 59:470-478.
55.
Larson EB, Omenn GS, Magno J. The impact of computed tomography on the care of patients with suspected
hydrocephalus. Am J Roentgenol 1978; 131:41-44.
56.
Larson EB, Omenn GS, Loop JW. Computed tomography of the brain in patients with suspected cerebrovascular disease:
impact of a new technology on patient care. Am J Roentgenol 1978; 131:35-40.
57.
Davenport SLH, O'Nuallain S, Omenn GS, Wilkus RJ. Usher syndrome in four hard-of-hearing siblings. Pediatrics
1978; 62:578-583.
58.
Omenn GS, McKusick VA. The association of Waardenburg syndrome and Hirschsprung megacolon. Am J Med Genet
1979; 3:217-223.
59.
Omenn GS. Psychopharmacogenetics: an overview and new approaches. Hum Genet 1978; Suppl. 1:83-90.
60.
Omenn GS, Smith LT, Hanson DR. Pharmacogenetic investigations of platelet uptake of serotonin. III. Serotonin uptake
in platelets and brain synaptosomes from young and aged Macaca nemestrina. In: Bowden DM, editor. Aging in nonhuman primates. New York: Raven Press, 1979:100-105.
61.
Farquhar MN, Kosky KJ, Omenn GS. Gene expression in brain as a function of age in Macaca nemestrina. In: Bowden
DM, editor. Aging in non-human primates. New York: Raven Press, 1979:71-79.
62.
Omenn GS, Ball JR. The role of health technology evaluation: a policy perspective. In: Goldman J, editor. Health care
technology evaluation. New York: Springer-Verlag, 1979:5-32.
63.
Rockey PH, Fantel J, Omenn GS. Discriminatory aspects of pre-employment low back x-ray examinations in the railroad
industry. Am J Law Med 1979; 5:197-214.
64.
Larson EB, Omenn GS, Lewis H. Diagnostic evaluation of headache: impact of computed tomography and cost
effectiveness. JAMA 1980; 243:359-362.
65. Omenn GS, Hall JG, Hansen KD. Genetic counseling for adoptees at risk for specified inherited disorders. Am J Med
Genet 1980; 5:157-164.
66.
Hrubec Z, Omenn GS. Evidence of genetic predisposition to alcoholic cirrhosis and psychosis: twin concordances for
alcoholism and its biological end points by zygosity among male veterans. Alcoholism: Clinical and Experimental
Research 1981; 5:207-215.
67.
Lave LB, Omenn GS, Heffernan KD, Dranoff G. A model for selecting short-term tests of carcinogenicity. J Am Col
Tox 1983; 2:125-130.
68.
Chen S-H, Omenn GS. Human neuron-specific enolase: genetic and developmental studies. J Neurogenet 1984;
1:159-164.
69.
Eaton DL, Kalman D, Garvey D, Morgan M, Omenn GS. Biological availability of lead in a paint aerosol. 2.
Absorption, distribution, and excretion of intratracheally instilled lead paint particles in the rat. Toxicol Lett 1984;
22:307-3l3.
70.
Goodman GE, Omenn GS, Feigl P, Kleinman GD, Lund B, Thomas DB, Henderson MM, Prentice R. Chemoprevention
of lung cancer with retinol/beta-carotene. Meyskens FL and Prasad KN, editors. Vitamins and cancer--human cancer
prevention by vitamins and micronutrients. Clifton, New Jersey: Humana Press, 1985: 341-350.
71.
Prentice RL, Omenn GS, Goodman GE, Chu J, Henderson MM, Feigl P, Kleinman GD, Thomas DB, Hutchinson ML,
Lund B, Day RW. Rationale and design of cancer chemoprevention studies in Seattle. J Natl Cancer Inst: Monograph
Series, No. 69, 1986:249-258.
72.
Lave LB, Omenn GS. Cost-effectiveness of short-term tests for carcinogenicity. Nature 1986; 324:29-34.
73.
Omenn GS, Ehreth JS. A new look for Medicaid. Bus & Health 1986; 4:7-11.
74.
Childs MT, Dorsett CS, Failor A, Roidt L, Omenn GS. Effect of shellfish consumption on cholesterol absorption in
normolipidemic men. Metab 1987; 36:31-35.
75.
Omenn GS. Lessons from a fourteen-state study of Medicaid. Health Affairs 1987; 6(Spring):118-122.
76.
Costa LG, Richter RJ, Murphy SD, Omenn GS, Motulsky AG, Furlong CE. Species differences in serum paraoxonase
correlate with sensitivity to paraoxon toxicity. In: Costa LG, Galli CL, Murphy SD, editors. Toxicology of pesticides:
experimental, clinical and regulatory aspects. Proceedings of the NATO Advanced Study Institute on Toxicology of
Pesticides. Heidelberg: Springer-Verlag, 1987:263-266. (NATO ASI Series, Vol. H13.)
77.
Kalman DA, Goodman GE, Omenn GS, Bellamy G, Rollins B. Micronutrient assay for cancer prevention clinical trials:
serum retinol, retinyl palmitate, alpha-carotene, and beta-carotene with the use of high-performance liquid
chromatography. JNCI 1987; 79:975-982.
78.
Thompson B, Omenn GS, Sexton M, Breitenstein B, Hessol N, Curry S, Michnich M, Peterson A. Worksite smoking
cessation: a test of two programs. In: Engstrom P, Mortenson LE, Anderson PN, editors. Advances in cancer control:
the war on cancer--15 years of progress. Prog Clin Biol Res 1987; 248:93-100.
79.
Omenn GS, Goodman GE, Kleinman GD, Rosenstock L, Barnhart S, Feigl P, Thomas DB, Kalman D, Lund B, Prentice
RL, Henderson MM. The role of intervention studies in ascertaining the contribution of dietary factors in lung cancer: the
Seattle chemoprevention trial of retinoids in asbestos-exposed workers. Ann NY Acad Sci 1988;534:575-583.
80.
Omenn GS, Goodman G, Rosenstock L, Barnhart S, Lund B, Thornquist M, Feigl P. Cancer chemoprevention with
vitamin A and beta-carotene in populations at high-risk for lung cancer. In: Cerutti PA, Nygaard OF, Simic MG, editors.
Anticarcinogenesis and Radiation Protection. New York: Plenum Press, 1988:279-283.
81.
Roidt L, White EM, Goodman GE, Wahl PW, Omenn GS, Rollins B, Karkeck JM. Association of food frequency
questionnaire estimates of vitamin A intake with serum vitamin A levels. Am J Epidemiol 1988; 128:645-54.
82.
Omenn GS. A double-blind randomized trial with beta-carotene and retinol in persons at high risk of lung cancer due to
occupational asbestos exposures and/or cigarette smoking. Public Health Rev 1988; 16:99-125.
83.
Omenn GS, Lave LB. Scientific and cost-effectiveness criteria in selecting batteries of short-term tests. Mutation
Research 1988; 205:41-49.
84.
Lave LB, Omenn GS. Screening toxic chemicals: how accurate must tests be? J Am Col Tox 1988; 7:565-74.
85.
Lave LB, Ennever F, Rosenkranz S, Omenn GS. Information value of the rodent bioassay. Nature 1988; 336:
631-633.
86.
Boatman ES, Covert D, Kalman D, Luchtel D, Omenn GS. Physical, morphological, and chemical studies of dusts
derived from the machining of composite-epoxy materials. Environ Research 1988; 45:242-55.
87.
Hermanson B, Omenn GS, Kronmal RA, Gersh BJ. Beneficial six-year outcomes of smoking cessation in older men and
women with coronary artery disease: results from the CASS registry. N Engl J Med 1988; 319:1365-9.
88.
Omenn GS, Thompson B, Sexton M, Hessol N, Breitenstein B, Curry S, Michnich M, Peterson A. A randomized
comparison of worksite-sponsored smoking cessation programs. Am J Prev Med 1988; 4:261-267.
89.
Curry S, Thompson B, Sexton M, Omenn GS. Psychosocial predictors of outcome in a worksite smoking cessation
program. Am J Prev Med 1989; 5:2-7.
90.
Omenn GS, Goodman GE, Thornquist M, Rosenstock L, Barnhart S and Feigl P. Chemoprevention of lung cancer with
beta-carotene and retinol in persons at high risk due to asbestos occupational exposures and/or cigarette smoking, a
double-blind randomized trial. In: Wehner, AP, editor. Biological Interaction of Inhaled Mineral Fibers and Cigarette
Smoke. Proceedings of an International Symposium/Workshop, Seattle, Washington: Battelle Press, 1989:121-143.
91.
Costa LG, McDonald BE, Murphy SD, Omenn GS, Richter RJ, Motulsky AG and Furlong CE. Serum paroxonase and its
influence on paraoxon and chlorpyrifos-oxon-toxicity in rats. Toxicol Appl Pharmacol 1990; 103:66-76.
92.
Hermanson B, Vlietstra RE, Kronmal RA, Gersh BJ, Omenn GS. Quitting smoking: Effect on survival of patients with
proven coronary artery disease. Cardiology Board Review 1990; 7:111-121.
93.
Omenn GS, Omiecinski CJ, Eaton DL. Eco-genetics of chemical carcinogens. In: Cantor CR, Caskey CT, Hood LE,
Kamely D, Omenn GS, editors. Biotechnology and Human Genetic Predisposition to Disease. New York: Wiley-Liss,
Inc., 1990; 126:81-93.
94.
Barnhart S, Thornquist M, Omenn GS, Goodman G, Feigl P, Rosenstock L. The degree of roentgenographic
parenchymal small opacities attributable to smoking among asbestos exposed subjects. Am Rev Respir Dis 1990;
141:1102-1106.
95.
Ennever FK, Rosenkranz HS, Lave LB, Omenn GS. Value-of-information analysis of testing strategies: Estimating the
effect of uncertainty about the proportion of chemicals that are true human carcinogens. In: Mendelsohn M, Albertini,
editors. Mutation and the Environment: Carcinogenesis. New York: Wiley-Liss, Inc., 1990; 295-304.
96.
Omenn GS, Anderson KW, Kronmal RA, Vlietstra MB. The temporal pattern of reduction of mortality risk after
smoking cessation. Am J Prev Med 1990; 6:251-257.
97.
Omenn GS. Future directions in cancer eco-genetics. In: Bloom A, editor. Genetic Susceptibility to Cancer. Mutation
Research Suppl. The Netherlands: Elsevier Science Publishers, 1991; 247:283-291.
98.
Omenn GS, Goodman G, Grizzle J, Thornquist M, Rosenstock L, Barnhart S, Anderson G, Balmes J, Cherniack M,
Cone J, Cullen M, Glass A, Keogh J, Meyskens F, Valanis B. CARET, the beta-carotene and retinol efficacy trial to
prevent lung cancer in asbestos-exposed workers and in smokers. In: Sluyser M, editor. Asbestos-Related Cancer.
England, Simon & Schuster, 1991; 302-315, and Anti-Cancer Drugs 1991; 2:79-86.
99.
Grizzle J, Omenn G, Goodman G, Thornquist M, Rosenstock L, Barnhart S, Balmes J, Cherniack M, Cone J, Cullen M,
Glass A, Keogh J, Valanis B. Design of the beta-carotene and retinol efficacy trial (CARET) for chemoprevention of
cancer in populations at high risk: Heavy smokers and asbestos-exposed workers. In: Pastorino U, Hong WK, ed.
Chemoimmuno Prevention of Cancer. NY: Stuttgart; and Thiemes Med. Pubs., 1991; 167-176.
100. Thornquist MD, Patrick DL, Omenn GS. Participation and adherence among older men and women recruited to the Beta-
Carotene and Retinol Efficacy Trial (CARET) to prevent lung cancer in heavy smokers and in asbestos-exposed workers.
The Gerontologist 1991; 31:593-597.
101. Goodman G, Omenn GS. Lung cancer chemoprevention in heavy cigarette smokers and asbestos-exposed workers. The
Cancer Bulletin 1991; 43:534-537.
102. LaCroix A, Omenn GS. Older adults and smoking. Clinics in Geriatric Medicine 1992; 8:69-87.
103. Omenn GS, Goodman G, Grizzle J, Thornquist M, Rosenstock L, Barnhart S, Anderson G, Balmes J, Cherniack M,
Cone J, Cullen A, Glass A, Keogh J, Meyskens, Jr. F, Valanis B, Williams, Jr. J. Recruitment for CARET, the carotene and retinol efficacy trial to prevent lung cancer in smokers and in asbestos-exposed workers. West J Med 1992;
156:540-544.
104.
Kosorok MR, Omenn GS, Diehr P, Koepsell TD, Patrick DL. Conditions associated with restricted activity days among
older adults. Am J Public Health 1992; 82:1263-1267.
105.
Omenn GS. The beta-carotene and retinol efficacy trial to prevent lung cancer in high-risk population. Public Health
Rev 1991/92; 19:205-208.
106. Goodman GE, Omenn GS. Carotene and retinol efficacy trial: lung cancer chemoprevention trial in heavy cigarette
smokers and asbestos-exposed workers. In Newell GR, Hong WK editors. The Biology and Prevention of Aerodigestive
Tract Cancers. New York: Plenum Press, 1992; 137-140.
107.
Kronmal RA, Cain KC, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age: a report
based on the Framingham data. Arch Intern Med 1993; 153:1065-1073.
108.
Omenn GS. CARET, the beta-carotene and retinol efficacy trial to prevent lung cancer in asbestos-exposed workers and
in smokers. In: Peters GA, Peters BJ, editors. Asbestos Control and Medical Treatment. Sourcebook on Asbestos
Diseases: Medical, Legal, and Engineering Aspects. Salem, New Hampshire: Butterworth Legal Publishers, 1993; 7:219241.
109.
Omenn GS, Goodman GE, Thornquist MD, Rosenstock L, Barnhart S, Gylys-Colwell I, Metch B, Lund B. CARET, The
carotene and retinol efficacy trial to prevent lung cancer in high-risk populations: pilot study with asbestos-exposed
workers. Cancer Epidemiology Biomarkers & Prevention 1993; 2:381-387.
110.
Goodman GE, Omenn GS, Thornquist MD, Lund B, Metch B, Gylys-Colwell I. The carotene and retinol efficacy trial
(CARET) to prevent lung cancer in high risk populations: pilot study with cigarette smokers. Cancer Epidemiology
Biomarkers & Prevention 1993; 2:389-396.
111.
Brodkin CA, Barnhart S, Anderson G, Checkoway H, Omenn GS, Rosenstock L. Correlation between respiratory
symptoms and pulmonary function in asbestos-exposed workers. Am Rev Respir Dis 1993; 148:32-37.
112.
Thornquist M, Omenn GS, Goodman GE, Grizzle J, Rosenstock L, Barnhart S, Anderson GL, Hammar S, Balmes J,
Cherniack M, Cone J, Cullen MR, Glass A, Keogh JP, Meyskens F, Valanis B, Williams Jr. JH. Statistical design of the
carotene and retinol efficacy trial (CARET). Controlled Clin Trials 1993; 14:308-324.
113.
Thornquist, MD, Urban N, Tseng A, Edelstein C, Lund B, Omenn GS. Research cost analyses to aid in decision making
in the conduct of a large prevention trial, CARET. Controlled Clin Trials 1993; 14:325-339.
114.
Omenn GS, Cain KC, Ye Z, Kronmal RA. Lowering total cholesterol level in the older adult raises serious questions.
Cardiology Board Review 1994; 11:37-41.
115. Omenn GS, Goodman G, Thornquist M, Grizzle J, Rosenstock L, Barnhart S, Balmes J, Cherniack M, Cullen M, Glass A,
Keogh J, Meyskens F, Valanis B, Williams J. The -carotene and retinol efficacy trial (CARET) for chemoprevention of
lung cancer in high-risk populations: smokers and asbestos-exposed workers. Cancer Research 1994; 54:2038s-2043s.
116. Goodman GE, Metch BJ, Omenn GS. The effect of long-term beta-carotene and retinol administration on the serum
concentrations of alpha tocopherol. Cancer Epidemiology, Biomarkers & Prevention 1994; 3:429-432.
117. Omenn GS, Goodman GE, Thornquist M, Brunzell JH. Long term vitamin A does not produce clinically-significant
hypertriglyceridemia: results from CARET, the -carotene and retinol efficacy trial. Cancer Epidemiol, Biomarkers &
Prevention 1994; 3:711-713.
118.
Omenn GS, Stuebbe S, Lave L. Predictions of rodent carcinogenicity testing results: interpretation in light of the LaveOmenn value-of-information model. Molecular Carcinogenesis 1995; 14:37-45.
119.
Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk
factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274:1049-1057.
120.
Carter WB, Martin M, Omenn GS, Vuturo A, Breslow L, Towns B, Landis M, Wood DW, Crump C, Kozma C, Williams
OD, Gottlieb N, Grunbaum JA, Labarthe DR. Characteristics of health promotion programs in federal worksites: case
study findings from the FEW Project. Amer J Health Promotion 1995; 10:140-147.
121.
Brodkin CA, Barnhart S, Checkoway H, Balmes J, Omenn GS, Rosenstock L. Longitudinal pattern of reported
respiratory symptoms and accelerated ventilatory loss in asbestos-exposed workers. Chest 1996; 109:120-126.
122.
Omenn GS, Goodman GE, Thornquist, MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens, Jr. FL, Valanis B,
Williams, Jr. JH, Barnhart S, Hammar S. Effects of a combination of beta-carotene and vitamin A on lung cancer and
cardiovascular disease. New Engl J Med 1996; 334:1150-1155.
123.
Omenn GS, Goodman G, Thornquist M, Barnhart S, Balmes J, Cherniack M, Cullen M, Glass A, Keogh J, Liu D,
Meyskens F, Perloff M, Valanis B, Williams J. Chemo-prevention of lung cancer: the -Carotene and Retinol Efficacy
Trial (CARET) in high-risk smokers and asbestos-exposed workers. In: M Hakama, V Beral, E Buiatti, J Faivre, D
Parkin, eds. Chemoprevention in Cancer Control. IARC Scientific Publications No. 136, Lyon: International Agency for
Research on Cancer 1996; 67-85.
124.
Omenn GS. Micronutrients (vitamins and minerals) as cancer-preventive agents. In: M Hakama, V Beral, E Buiatti,
J Faivre, DM Parkin eds. Principles of Chemo-prevention. IARC Scientific Publications No. 139, Lyon: International
Agency for Research on Cancer 1996; 33-45.
125.
Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Jr, Valanis B,
Williams JH, Jr, Barnhart S, Cherniack MG, Brodkin CA, Hammar S. Risk factors for lung cancer and for intervention
effects in CARET, the beta-carotene and retinol efficacy trial. JNCI 1996; 88:1550-1559.
126.
Goodman GE, Thornquist M, Kestin M, Metch B, Anderson G, Omenn GS, CARET Co-investigators. The association
between participant characteristics and serum concentrations of beta-carotene, retinol, retinyl palmitate and alphatocopherol among participants in the carotene and retinol efficacy trial (CARET) for prevention of lung cancer. Cancer
Epidemiology, Biomarkers and Prevention 1996; 5:815-821.
127.
Chuwers P, Barnhart S, Blanc P, Brodkin CA, Cullen M, Kelly T, Keogh J, Omenn GS, Williams J, Balmes JR. The
protective effect of -carotene and retinol on ventilatory function in an asbestos-exposed cohort. Am J Respir Crit Care
Med 1997; 155:1066-1071.
128.
Brodkin CA, McCullough J, Stover B, Hammar S, Omenn GS, Checkoway H, Metch B, Barnhart S. Lobe of origin and
histologic type of lung cancer associated with asbestos exposure in the beta-carotene and retinol efficacy trial. Am J Ind
Med 1997;32:582-591.
129.
Barnhart S, Balmes J, Keogh J, Cullen M, Cherniack M, Brodkin C, Stover B, Valanis B, Glass A, Metch B, Rosenstock
L, Omenn GS. The CARET asbestos-exposed cohort: Description of asbestos exposure, demographic findings, asbestos
exposure and comparison to other asbestos-exposed cohorts. Am J Ind Med 1997;32:573-581.
130. Omenn G, CARET co-authors. Response to Leo Ma, Lieber CS, letter to the editor: Risk factors for lung cancer and
intervention effects in CARET. JNCI 89:1722-1723, Nov 19, 1997.
131. Omenn G. Risk factors for lung cancer and for intervention effects in CARET. Response (letter). JNCI 89:325-326, Feb
19, 1997.
132. Omenn G, Thornquist M. Beta-carotene and the risk of lung cancer. Response(letter) JNCI 89:457-458, Mar 19, 1997.
133.
Omenn G, Beresford S, Motulsky A. Preventing coronary heart disease - B vitamins and homocysteine. Circulation
1998;97-421-424.
134.
Omenn GS. Interpretations of the Linxian vitamin supplement chemoprevention trials. Epidemiol 1998;9:1-4.
135.
Goodman GE, Valanis B, Meyskens FL, Williams J Jr., Metch B, Thornquist MD, Omenn GS. Strategies for recruitment
to a population-based lung cancer prevention trial:the CARET experience with heavy smokers. Cancer Epidemiol
Biomarkers & Prev 1998;7:405-412.
136. Bartell SM, Ponce RA, Takaro TK, Omenn GS, Zerbe RO, Faustman EM. Value-of-information analyses for
biomarkers: susceptibility to chronic beryllium disease at US DOE sites. Proc Topical Meeting on Risk-Based
Performance and Decision Making, American Nuclear Society, Pasco WA, Apr 5-8, 1998; pp. 205-213.
137. Bartell SM, Ponce RA, Takaro TK, Zerbe RO, Omenn GS, Faustman EM. Risk estimation and value-ofinformation analysis for three proposed genetic screening programs for chronic beryllium disease prevention. Risk
Analysis 2000;20:87-99.
138.
Takaro TK, Ertel K, Salazar MK, Beaudet N, Stover B, Hagopian A, Omenn GS, and Barnhart S. Barriers and
solutions in implementing occupational health and safety services at a large nuclear weapons facility. J Healthcare
Quality 2000;22:29-37.
139.
Bowen D, Thornquist M, Goodman G, Omenn GS, Anderson K, Barnett M, Valanis B. Effects of incentive items on
participation in a randomized chemoprevention trial. J Health Psychology 2000;5:109-115.
140.
Nallamothu BK, Fendrick AM, Rubenfire M, Saint S, Bandekar R, Omenn GS. Potential clinical and economical
effects of homocyst(e)ine lowering. Archives of Internal Medicine 2000;160: 3406-3412.
141.
Goodman GE, Schaffer S, Bankson DD, Hughes MP, Omenn GS, CARET co-investigators. Predictors of serum
selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiol
Biomarkers Prev 2001; 10:1069-1076.
142. Thornquist MD, Edelstein C, Goodman GE, Omenn GS. Streamlining IRB review in multisite trials through singlestudy IRB Cooperative Agreements: experience of the -Carotene and Retinol Efficacy Trial (CARET). Controlled
Clinical Trials 2002; 23: 80-86.
143. Chinnaiyan A, Coffey D, Forrest S, Goldberg E, Holland J, Kepler T, Maley C, Mitchell M, Montie J, Morowitz H,
Nelson W, Omenn G, et al. Merging bottom-up and top-down approaches to study prostate cancer biology.
Complexity 2002; 7(5): 22-30.
144. Creighton C, Kuick R, Misek D, Rickman D, Brichory F, Rouillard JM, Omenn GS, Hanash S. Profiling of
pathway-specific changes in gene expression following growth of human cancer cell lines transplanted into mice.
Genome Biology 2003; 4:R46.
145. Goodman G, Schaeffer S, Omenn GS, Chen C, and King I. The association between lung and prostate cancer risk,
and serum micronutrients. Cancer Epidemiol Biomarkers Prev 2003; 12: 518-526.
146. Neuhouser M, Patterson R, Thornquist M, Omenn GS, King I, Goodman G. Fruits and vegetables are associated
with lower lung cancer risk only in the placebo arm of the ß-Carotene and Retinol Efficacy Trial (CARET). Cancer
Epidemiol Biomarkers Prev 2003; 12: 350-358.
147.
Bowen DJ, Thornquist M, Anderson K, Barnett M, Powell C, Goodman G, Omenn GS. Stopping the active
intervention: CARET. Controlled Clinical Trials 2003;24:39-50.
148.
Bouwman K, Qiu J, Zhou H, Schotanus M, Mangold L, Vogt R, Erlandson E, Trenkle J, Partin AW, Misek D,
Omenn GS, Haab BB, Hanash S. Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate
cancer serum immunoreactivity. Proteomics 2003; 3:2200-2207.
149.
Qiu J, Madoz-Gurpide J, Misek DE, Kuick R, Brenner DE, Michailidis G, Haab BB, Omenn GS, Hanash SM.
Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J
Proteome Research, 2004; 3(2):261-7.
150.
Imafuku Y, Omenn GS, Hanash S. Proteomics Approaches to Identify Auto-Immune Antibodies as Cancer Biomarkers.
Disease Markers special issue Mass Spectrometry and Biomarker Development, 2004; 20(3):149-153.
151. Omenn GS. Advancement of Biomarker Discovery and Validation through the HUPO Plasma Proteome Project.
Disease Markers special issue Mass Spectrometry and Biomarker Development, 2004; 20(3):131-134.
Review and Policy Papers
1.
Gill TJ III, Omenn GS. Studies on the structure of synthetic polypeptides in solution by polarization of fluorescence
techniques. Adv Chem 1967; 63:189-216.
2.
Omenn GS. Recognition of ectopic hormone syndromes produced by tumors. In: The clinical delineation of birth
defects, Part X, Endocrine Systems. Birth Defects: Original Articles Series 1971; 7:73-78.
3.
Omenn GS. Ectopic hormone syndromes associated with tumors in childhood. Pediatrics 1971; 47:613.
4.
Gelehrter TD, Motulsky AG, Omenn GS. Genetic control mechanisms in man and other mammals. Science 1970;
169:791-792.
5.
Omenn GS, Motulsky AG. Brain, genetics, and behavior. Science 1971; 169:791-792.
6.
Sutton HE, Omenn GS. Fabry's disease: the search for a regulatory gene mutation in man. Am J Hum Genet 1972;
24:343-347.
7.
Omenn GS, McDevitt HO. Immunology and genetics. Science 1972; 177:904-906.
8.
Omenn GS, Motulsky AG. Psycho-pharmacogenetics. In: Kaplan AR, editor. Human behavior genetics. Springfield: CC
Thomas; 1973. p. 363-384. (Note: this article is reprinted in Year Book of Drug Therapy, Chicago: Year Book Medical
Publishers; 1973. p. 5-26.)
9.
Omenn GS. Genetic approaches to the syndrome of minimal brain dysfunction. Ann NY Acad Sci 1973; 205:212-222.
10.
Motulsky AG, Omenn GS. Human behavior, genes, and society. In: Proceedings of Birth Defects Institute Symposium
II, Heredity and Society. New York: Academic Press; 1972. p. 93-113.
11.
Omenn GS. Genetic engineering: present and future. In: Williams RH, editor. To live and to die: when, why and how.
New York: Springer-Verlag; 1973. p.48-63.
12.
Omenn GS, Caspari E, Ehrman L. Behavior genetics and educational policy. Epilogue. In: Ehrman L, Omenn GS,
Caspari E, editors. Genetics, environment, and behavior: implications for educational policy. New York: Academic
Press; 1972. p. 307-310.
13.
Omenn GS, Motulsky AG. Pharmacogenetics and mental disease (Editorial). Psychol Med 1974; 4:125-9. Republished
in The Spectrum of Psychiatric Research. M Shepard, editor. Cambridge: Cambridge Univ. Press, 1974:86-90.
14.
Omenn GS. Chemical basis of inheritance. In: Fraser GR, Mayo O, editors. Textbook of human genetics. Oxford:
Blackwell; 1974. p. 66-114.
15.
Omenn GS. L`Eco-Genetique. La variation determinee genetiquement dans l`action biologique des agents externes.
Premier Congres Mondial de l`Environment, Medecine et Biologie, Paris, 1974. Elsevier Publishing Company, 1974.
16.
Omenn GS. The role of government in energy. Proceedings, Symposium on Energy and Society, St. Cloud, MN,
1974:10-22.
17.
Omenn GS. Genetic mechanisms in human behavioral development. In: Schaie KW, Anderson VE, McClearn GE,
Money J, editors. Developmental human behavior genetics: nature-nurture redefined. Lexington, MA: DC Heath; 1975.
p. 93-111.
18.
Omenn GS, Schrott HG. Prenatal prediction of autosomal dominant diseases by linkage studies: myotonic dystrophy.
Acta Genet Med Gemellol 1974; 23:221-228.
19.
Omenn GS, Motulsky AG. Intrauterine diagnosis and genetic counseling: implications for psychiatry in the future. In:
Hamburg DA, Brodie HKH, editors. American Handbook of Psychiatry VI, 3rd ed. New York: Basic Books; 1975, p.
554-571.
20.
Motulsky AG, Omenn GS. Biochemical genetics and psychiatry. In: Fieve RR, Rosenthal D, Brill H, editors. Genetic
research in psychiatry. Baltimore: Johns Hopkins University Press; 1975. p. 3-14.
21.
Omenn GS, Motulsky AG. Pharmacogenetics: clinical and experimental studies in man. In: Eleftheriou BE, editor.
Psychopharmacogenetics. New York: Plenum Press; 1975. p. 183-228.
22.
Omenn GS. Alcoholism: A pharmacogenetic disorder. In: Mendlewicz J, editor. Genetics and psychopharmacology.
New York: S Karger; 1975. p. 12-22.
23.
Omenn GS. Scientific manipulation of the unborn. 1975 National Medicolegal Symposium of the American Bar
Association and American Medical Association. Chicago: AMA, 1975:11-19.
24.
Omenn GS. Genetic factors in the development of mental retardation. In: Robinson NM, Robinson HB, with
contributions by Omenn GS and Campione JC. The mentally retarded child: a psychological approach. Revised edition,
Chapter 3. New York: McGraw-Hill; 1976. p. 51-75.
25.
Omenn GS. Genetic syndromes in mental retardation. In: Robinson NM, Robinson HB, with contributions by Omenn GS
and Campione JC, editors. The mentally retarded child: a psychological approach. Revised edition, Chapter 4. New
York: McGraw-Hill; 1976. p. 76-107.
26.
Omenn GS. The physical environment as a factor in mental retardation. In: Robinson NM, Robinson HB, with
contributions by Omenn GS and Campione JC, editors. The mentally retarded child: a psychological approach. Revised
ed., Chapter 5. New York: McGraw-Hill; 1976. p. 108-133.
27.
Omenn GS. Common clinical disorders associated with mental retardation. In: Robinson NM, Robinson HB, with
contributions by Omenn GS and Campione JC, editors. The mentally retarded child: a psychological approach. Revised
ed., Chapter 6. New York: McGraw-Hill; 1976. p. 134-146.
28.
Omenn GS. Inborn errors of metabolism: clues to understanding human behavioral disorders. Behav Genet 1976; 6:263284.
29.
Schaller JG, Omenn GS. The histocompatibility system and human disease. J Pediatr 1976; 88:913-925.
30.
Omenn GS. Critical choices in the area of biomedical ethics. In: Qualities of Life (Critical Choices for Americans, Vol.
7). Lexington, MA: DC Heath; 1976. p. 317-345.
31.
Omenn GS, Motulsky AG. Farmacogenetica. Tribuna Medica Revision (Psicofarmacologia II) 6(34):23-39, 1976.
32.
Omenn GS. Behavior genetics. In: Birren J, editor. Handbook on the psychology of aging. New York: Van Nostrand
Reinhold; 1976. p. 190-218.
33.
Omenn GS. Intrauterine diagnosis and genetic counseling in psychiatry. Social Biol 1976; 23:142-157.
34.
Omenn GS. Neurochemistry and behavior in man (Medical Progress). West J Med 1976; 125:434-451.
35.
Omenn GS. Emerging bioethical dilemmas in the provision of health services. In: Proceedings, Conference on Health,
Exposition of Science and Technology, California State Legislature, 1976.
36.
Omenn GS. Pharmacogenetics and aging. In: Elias MF, Eleftheriou BF, Elias PK, editors. Special review of
experimental aging research. Bar Harbor, ME: EAR, Inc.; 1976. p. 31-35.
37.
Omenn GS. Genetics of rheumatic diseases. In: First ARA Conference on Rheumatic Disorders of Childhood, Park City,
Utah, 1976. Arthritis Rheum 1977; 20:473-483.
38.
Omenn GS. Significance of histocompatibility genes in rheumatology. In: First ARA Conference on Rheumatic
Disorders of Childhood, Park City, Utah, 1976. Arthritis Rheum 1977; 20:484-496.
39.
Omenn GS. Genetics and cardiovascular disease. In: Willerson JT, Sanders C, editors. Clinical cardiology. New York:
Grune & Stratton; 1977. p. 453-464.
40.
Omenn GS. Polymorphisms, genetic load, and the malaria story. In: Progress in Human Nutrition, Vol. II, Margen S,
Ogar R, editors. Westport, CN:AVI Publishing; 1978. p. 169-187.
41. Omenn GS. Genetic counseling. In: Goldenson R, Dunham JR, Dunham C, editors. Handbook on the Handicapped. New
York: McGraw-Hill; 1978. p. 241-248.
42. Omenn GS, Motulsky AG. Eco-genetics: genetic variation in susceptibility to environmental agents. In:
Cohen BH, Lilienfeld AM, Huang PC, editors. Genetic Issues in Public Health and Medicine. Springfield, IL:
CC Thomas; 1978, p. 83-111.
43.
Omenn GS. Prenatal diagnosis of genetic disorders. Science 1978;200:952-958.
44.
Omenn GS. Health care in the new China. Harvard Medical Alumni Bulletin March/April 1978; p. 16-21.
45.
Omenn GS. Ecogenetics: a view from the U.S. President's Science Advisory Office. Hum Genet 1978; Suppl 1:
179-184.
46.
Omenn GS. Genetics. Americana Annual/Encyclopedia Yearbook, 1979; p.219.
47.
Omenn GS. Eco-genetics: Human variation in susceptibility to environmental agents. In: Proceedings, CSIC/UNESCO
Symposium on Biology and Ethics. R. De Vicente, editor. Madrid: Consejo Superior de Investigacions Cientificas;
1979. p. 229-244.
48.
Omenn GS. Pharmacogenetic approaches to alcohol and drug abuse. In: Pickens R, Heston L, editors. Psychiatric
Factors in Drug Abuse. New York: Grune and Stratton; 1979. p. 183-198.
49.
Omenn GS. International health: from the perspective of the Carter Administration. In: Pharmaceuticals for Developing
Countries, Institute of Medicine Conference Proceedings. Washington, DC: National Academy of Sciences; 1979, p.
168-174.
50.
Omenn GS, Blass JP. Genetic approaches to neurobiology. Nature 1979; 281:429-430.
51.
Omenn GS. Ectopic hormone syndromes associated with tumors in childhood. In: Kelley VC, editor. Practice of
Pediatrics. New York: Harper & Row; 1979. p.1-6.
52.
Omenn GS. Genetics and epidemiology: medical interventions and public policy. Soc Biol 1979; 26:117-125.
53.
Calkins DR, Dixon RL, Gerber CR, Zarin D, Omenn GS. Identification, characterization and control of potential human
carcinogens: a framework for Federal decision making. J Natl Cancer Inst 1980; 64:169-175.
54.
Prager DJ, Omenn GS. Research, innovation, and university-industry linkages. Science 1980; 207:379-384.
55.
Omenn GS. Genetics. Americana Annual/Encyclopedia Yearbook, 1980, p. 228.
56.
Omenn GS, Ball JR. Medical technologies: a perspective of the Carter Administration. Forum Med, June 1980,
374-375.
57.
Ball JR, Omenn GS. Genetics, adoption, and the law. In: Milunsky A, Annas GJ, editors. Genetics and the Law, II. New
York: Plenum Press; 1980. p. 269-281.
Omenn GS. Behavior genetics of aging. In: Stein DG, editor. The Psychobiology of Aging: Problems and Perspectives.
New York: Elsevier; 1980. p. 1-20.
58.
p.
59.
Hansen KD, Omenn GS. Genetic isolation of adoptees. J Pediar Ophthalmol Strabismus 1980; 17:215-219.
60.
Omenn GS. Presidential Commission on Bioethics launched. Bioethics Q 1980;2:76-83.
61.
Prager DJ, Omenn GS. Federal support of food and agricultural science: the quid pro quo. In: 1980 AAAS Symposium
on Federal Funding Philosophies, Policies, and Procedures: Impact on Research in the Food and Agricultural Sciences.
Berkeley, CA, Western Assn Agrl Expt Station Directors; 1980. p. 15-32.
62.
Omenn GS. Human genetics of high interest in China. Am J Med Genet 1980; 7:11-13.
63.
Omenn GS. Protein polymorphisms. In: Gershon ES, Matthysse S, Breakefield XO, Ciaranello RD, editors. Genetic
Research Strategies for Psychobiology and Psychiatry. Pacific Grove, CA: Boxwood Press; 1981,
p. 65-77.
64.
Omenn GS. Some practical strategies for clinical research. In: Gershon ES, Matthysse S, Breakefield XO, Ciaranello
RD, editors. Genetic Research Strategies for Psychobiology and Psychiatry. Pacific Grove, CA: Boxwood Press; 1981.
p. 399-404.
65.
Blass JP, Omenn GS. Molecular neurogenetics. Neurology 1981; 31:172-173.
66.
Omenn GS. Genetics. Americana Annual/Encyclopedia Yearbook, 1981; p.243.
67.
Omenn GS. Dysmentation from metabolic alterations. In: Williams RH, editor. Textbook of Endocrinology, 6th ed.
Philadelphia: WB Saunders; 1981. p. 673-684.
68.
Omenn GS, Simopoulos AP. National nutrition policy in the United States. In: Selvey N, White PL, editors. Nutrition in
the 1980s: constraints on our knowledge. New York: Alan R. Liss, Inc.; 1981. p. 473-379.
69.
Omenn GS. Government as a broker between private and public institutions in the development of recombinant DNA
applications. In: Proc. Battelle Conf. on Genetic Engineering. Reston, VA: 1981. Vol. 1, p. 34-46.
70.
Omenn GS. Science and public policy. In: Hickman FM, Kahle JB, editors. New Directions in Biology Teaching:
Perspectives for the 1980s. Reston, VA: Association of Biology Teachers; 1982. p. 447-457.
71.
Omenn GS. Genetics. In: Americana Annual/Encyclopedia Yearbook; 1982. p.225-226.
72.
Omenn GS. Engineering: lessons from medical schools. Science 1982; 215:1461.
73.
Omenn GS, Nathan RP. What's behind those block grants in health? New Engl J Med 1982; 306:1057-1060.
74.
Omenn GS. Eco-genetics: human variation in susceptibility to environmental agents. In: Heshem, Nemat, editor.
Preventable Aspects of Genetic Morbidity, vol. I. Genetic Chromosomal and Multifunctional Factors. Cairo, Egypt: Ain
Shams Univ.; 1982. p. 127-132.
75.
Omenn GS, Prager DJ. Research universities and the future: challenges and opportunities. In: Phillips D, Chen B,
editors. Research in the Age of the Steady-State University. Washington, DC: AAAS; 1982. p. 21-30.
76.
Omenn GS. Maternal and child health: use of health status indicators in coordinating and targeting Federal programs. J
Com Health, 1982; 7:194-210.
77.
Omenn GS. Medical genetics, genetic counseling, and behavior genetics. In: Fuller JL, Simmel EC, editors. Behavior
Genetics: Principles and Applications. New York: Lawrence Erlbaum Publ; 1982. p. 155-187.
78.
Omenn GS. Biochemical genetic approaches to human brain studies. In: Lieblich I, editor. The Genetics of the Brain.
Amsterdam: Elsevier Biochemical Press; 1982. p. 439-479.
79.
Omenn GS. Chemical and radiation hazards to children: implications for government. 84th Ross Conf on Pediatric
Research, 1982, p. 111-116.
80.
Omenn GS. Predictive identification of hypersusceptible individuals. J Occ Med 1982; 24:369-374.
81.
Aaron HJ, Burtless GT, Downs A, Russell L, Omenn GS, Breneman DW. Non-defense programs. In: Settling National
Priorities, 1983. Washington, DC: Brookings Institution; 1982. p. 101-149.
82.
Omenn GS. Taking university research into the marketplace. New Engl J Med 1982; 307:694-700.
83.
Omenn GS. Re-energizing the research university. Environ 1982; 24:49-51.
84.
Omenn GS. Preventing injuries, disability, and death at work (starting with vehicles and guns). JAMA 1982; 248:723724.
85.
Omenn GS. Pharmacogenetics. In: Eisdorfer C, editor. Annual Review of Gerontology and Geriatrics, Vol. III, New
York: Springer-Verlag; 1982. p. 27-51.
86.
Omenn GS, Rosenblatt R. Environmental medicine: a current and pressing clinical challenge. University of Washington
Medicine 1982; 9:2-3.
87.
Omenn GS. Environmental risk assessment: relation to mutagenesis, teratogenesis, and reproductive effects. J Am Coll
Tox 1983; 2:113-123.
88.
Omenn GS. Are kids afraid to become scientists? Science 83; September 1983, p. 18.
89.
Omenn GS. The Clean Air Act: an update. In: Panem S, editor. Public Policy, Science, and Environmental Risk,
Addresses Presented at a Workshop at the Brookings Institution, February 28, 1983. Washington, DC: The Brookings
Institution; 1983. p. 39-43.
90.
Omenn GS. University-corporate relations in science and technology: an analysis of specific models. In: Langfitt TW,
Hackney S, Fishman AP, Glowasky AV, editors. Partners in the Research Enterprise: University-Corporate Relations in
Science and Technology, Philadelphia: University of Pennsylvania Press; 1983, p. 20-32.
91.
Omenn GS. Genetic polymorphisms in man with increased susceptibility to environmental agents. Risk assessment and
environmental policy-making: characterization of effects, exposure, and susceptibility. In: Proc. U.S.-Egypt Seminar on
Environmental Management. A report by the National Institute of Environmental Health Sciences; 1983. p. 65-104 and
299-328.
92.
Omenn GS. A framework for reproductive risk assessment and surveillance. In: Legator MS, Rosenberg MJ, Zenick H,
editors. Environmental Influences on Fertility, Pregnancy, and Development. Strategies for Measurement and
Evaluation. New York: Alan R. Liss; 1984. p. 1-14. (Also: Teratogenesis, Carcinogenesis and Mutagenesis 1984; 4:114.).
93.
Omenn GS. Basic research as an investment in the Nation's future. In: Schechter AN, Goldberger RF, Dean A, editors.
The impact of protein chemistry on the biomedical sciences. (An International Symposium in Honor of Christian B.
Anfinsen). New York: Academic Press; 1984. p. 7-19.
94.
Omenn GS. Public policy issues. In: Weiss JO, Bernhardt BA, Paul NW, editors. Genetic Disorders and Birth Defects
in Families and Society. Weiss JO, Bernhardt BA, Paul NW, editors. Birth Defects: Original Article Series; 1984;
20:206-212.
95.
Omenn GS. Characterizing risks: utilizing knowledge about mechanisms. In: Tashjian AH Jr, editor. Molecular and
Cellular Approaches to Understanding Mechanisms of Toxicity. Boston: Harvard School of Public Health; 1984.
p.
224-245.
96.
Omenn GS, Morris SL. Occupational hazards to health care workers: report of a conference. Am J Ind Med 1984;
6:129-137.
97.
Omenn GS. Risk assessment, pharmacogenetics, and ecogenetics. In: Omenn GS, Gelboin H, editors. Banbury Report
16: Genetic Variability in Responses to Chemical Exposure. Cold Spring Harbor Laboratory, New York: 1984. p. 3-13.
98.
Omenn GS. Advances in genetics and immunology: the importance of basic research to prevention of occupational
diseases. Arch Env Hlth 1984; 39:173-184.
99.
Norman JG, Omenn GS. Graduate students and corporate research. Thought and Action 1984; 1:56-57.
100.
Omenn GS, Conrad DA. Implications of DRGs for clinicians. New Engl J Med 1984; 311:1314-1317.
101.
Omenn GS. The role of the Federal government in artificial organ programs. In: Shaw MW, editor. After Barney Clark:
Reflections on the Utah Artificial Heart Program. Austin: The University of Texas Press; 1984. p. 55-67.
102.
Omenn GS, Faustman-Watts E. Teaching risk assessment for environmental hazards to a multi-disciplinary graduate
student audience. In: DeRoos RL, editor. Environmental Health Risk Assessment Workforce Characteristics and Training
Needs. American Public Health Association, Environment Section; 1985.
103.
Omenn GS. Let federalism work in Medicaid. Op-ed, Wall Street Journal, April 26, 1985, p. 26.
104.
Dworkin RB, Omenn GS. Legal aspects of human genetics. Ann Rev Public Health 1985; 6:107-130.
105.
Omenn GS. Controlled testing and monitoring methods for microorganisms. In:Covello VT, Fiksel JR, editors. The
Suitability and Applicability of Risk Assessment Methods for Environmental Applications of Biotechnology. Washington,
DC:National Science Foundation Report no. NSF/PRA 8502286; August 1985. p. G 1-28. Also published in
Biotechnology Risk Assessment. Fiksel JR, Covello VT, editors. New York: Pergamon Press; 1986. p. 144-163.
106.
Conrad DA, Omenn GS. Medicare's new payment plan: a mixed blessing. Tech Rev 1985; 88:50-51,76.
107.
Omenn GS. Basic research as an investment in the future. Am J Roentgenology 1985; 145:1100-1112.
108.
Omenn GS. Genetic control of environmental pollutants: a conference review. Microb Ecol 1986; 12:129-134.
109.
Omenn GS. Susceptibility to occupational and environmental exposures to chemicals. In: Kalow W, Goedde HW,
Agarwal DP, editors. Ethnic Differences in Reactions to Drugs and Xenobiotics. New York: Alan R. Liss, Inc.; 1986. p.
527-545.
110.
Omenn GS. A framework for risk assessment for environmental chemicals. Washington Public Health, Summer 1986;
6:2-6.
111.
Omenn GS. Prenatal diagnosis and public policy. In: Milunsky A, editor. Genetic Disorders and the Fetus, Second Ed.
New York: Plenum Press; 1986. p. 861-879.
112.
Omenn GS. Health care technologies and health care delivery systems. Chapter 4. In: Johnston A, Sasson A, editors.
New Technologies and Development. Paris: UNESCO; 1986. p.149-202.
113.
Omenn GS, Merchant J, Boatman E, Dement JM, Kuschner M, Nicholson W, Peto J, Rosenstock L. Contribution of
environmental fibers to respiratory cancer. Environ Health Persp 1986; 70:51-56.
114.
Omenn GS. Occupational Hazards to Health Care Workers. Proc. American Conference of Governmental Industrial
Hygienists, September 10-12, 1986, p. 229-234, 1986.
115.
Omenn GS. Values in the debate over workplace safety and health: the rancorous rhetoric about regulation. Chapter 19.
In: Englehardt HT Jr, Caplan AL, editors. Scientific Controversies: Case Studies in the Resolution and Closure of
Disputes in Science and Technology. Cambridge University Press; 1987 p.437-464.
116.
Omenn GS. Heredity and environmental interactions. AND Research strategies. In: Goedde HW, Agarwal DP, editors.
Genetics and Alcoholism. New York: Alan R. Liss, Inc.; 1987. p. 323-325, 333-341.
117.
Omenn GS. On the science, art, and business of medicine. In: Greenberg W, Luce BR, Southby RMF, editors. Health
Care Technology Under Financial Constraints. Columbus, OH: Battelle Press; 1987. p. 3-17.
118.
Koenig JQ, Omenn GS. Genetic factors in non-neoplastic lung disease. In: Brain JD, Beck BD, Warren AJ, Shaikh RA,
editors. Variations in susceptibility to inhaled pollutants: identification, mechanisms, and policy implications.
Baltimore: Johns Hopkins University Press; 1987. p. 59-88.
119.
Omenn GS. The role of genetic differences in human susceptibility to pesticides. In: Costa LG, Galli CL, Murphy SD,
editors. Toxicology of pesticides: experimental, clinical and regulatory perspectives. Heidelberg: Springer-Verlag;
1987. p. 93-107.
120.
Omenn GS. University of Washington Center for Health Promotion in Older Adults. Perspectives on Prevention 1988;
2:50-55.
121.
Omenn GS. Genetic susceptibility and the estimation of risk. In: Gordis L, editor. Epidemiology and Health Risk
Assessment. New York: Oxford University Press; 1988. p. 92-104.
122.
Omenn GS. Risk assessment for potentially carcinogenic chemicals. ISI Atlas of Science/Pharmacology 1988; 2:91-94.
123.
Clever LH, Omenn GS. Hazards for health care workers. Ann Rev Public Health 1988; 9:273-303.
124.
DeRoos RL, Anderson PN, Berberich NJ, Maugens B, Omenn GS, Rentos PG. Observations on work force and training
needs for assessing environmental health risks. Public Health Reports 1988; 103:348-54.
125.
Omenn GS. Genetic investigations of alcohol metabolism and of alcoholism. Am J Hum Genet 1988; 43:579-581.
126.
Omenn GS. Chemoprevention of occupationally related lung cancer. Washington Public Health 1989; 7:35-36.
127.
Omenn GS. UW Center for Health Promotion in Older Adults: "Keeping Healthy Older People Healthy". Washington
Public Health 1989; 7:47-48.
128.
Lave LB, Omenn GS. Tons of Toxic Chemicals Above. Op-ed, The Christian Science Monitor, April 11, 1989, p. 19,
and Right-to-know law shocks polluters, too, Carnegie Mellon Magazine, Winter 1989; 8:48.
129.
Omenn GS, Bourquin AW. Risk assessment for biodegradation in pollution control and pollution cleanup. In:
Chakrabarty A, Kamely D, Omenn GS, editors. Biotechnology and Biodegradation. Woodlands, Texas: Portfolio
Publishing Co; 1990. p. 443-465.
130.
Omenn GS. Summation of Conference. In: Chakrabarty A, Kamely D, Omenn GS, eds: Biotechnology and
Biodegradation. Woodlands, Texas: Portfolio Publishing Co; 1990, p. 491-499.
131.
Omenn GS. A Healthier America: Health promotion and disease prevention objectives for the year 2000. In: Arnold
CB, editor. Proceedings of the 98th Ann Mtg Association of Life Insurance Medical Directors of America. Transactions
of ALIMDA, Tampa, Fl: Klay and Sons; 1990, p. 165-173.
132.
Omenn GS. Prevention and the elderly: what are appropriate policies? Health Affairs 1990; 9(Summer):80-93.
133.
Omenn GS. Preface to Volume 11 and Tribute to Lester Breslow. In: Breslow L, Fielding JE, Lave LB, editors. Ann
Rev Public Health 1990; 11:vii-ix.
134.
Omenn GS. Controlling your risk from tobacco. In: Luckman J, ed: Your Health: Personal and Social Dynamics.
Englewood Cliffs, NJ: Prentice Hall; 1990, p. 210-233.
135.
Omenn GS. How laboratory and epidemiologic research contribute to understanding of human health risks. In:
Proceedings of the 1989 EPRI Utility Seminar: Power-Frequency Electric and Magnetic Field Laboratory Research. Palo
Alto, CA, Electric Power Research Institute; 1989. 20 pp.
136.
Omenn GS. Immunodeficiency, erythrophagocytic lymphohistiocytosis. In: Buyse ML, editor.: Birth Defects
Encyclopedia. Blackstone Scientific Publications; 1990, p. 958-959.
137.
Omenn GS. Hazardous chemical wastes, a global problem with biotechnology solutions. In: BIDEC International
Symposium on Biotechnology for Solving Global Environmental Problems, Tokyo: 1990. p. 11-21.
138.
Omenn GS. Eco-genetics: genetics and susceptibility to cancer. Health & Environment Digest 1991; 4(11):1-3.
139.
Goldstein BD, Omenn GS. The crusade to remove asbestos has gone too far. Op-ed, The Hartford Courant, April 1991.
140.
Omenn GS. Do we know enough to take a risk-based approach? In: Setting Environmental Priorities: The Debate About
Risk. EPA Journal 1991; 17(2):33.
141.
Omenn GS. Introduction to symposium on selected clinical syndromes associated with aging. In: Omenn GS, Fielding,
JE, Lave LB, editors. Annual Review of Public Health. Palo Alto: Annual Reviews Inc.; 1992. 13; p. 411-413.
142.
Omenn GS. Environmental biotechnology: biotechnology solutions for hazardous chemical wastes and oil spill cleanup.
Journal of Clean Technology and Environmental Sciences 1992; 2:47-55, and In: Molak V, editor. The Alaskan story.
Princeton, NJ: Princeton Scientific Publishing Co., Inc.; 1992. p. 97-106.
143.
Omenn GS. Environmental biotechnology: biotechnology solutions for a global environmental problem, hazardous
chemical wastes. In: Lin RS, Liao, CS, editors. Proceedings of the 1990 International Symposium on Health,
Environment, and Social Change, Taiwan: National Taiwan University; 1992. p. 183-189.
144.
Omenn GS. Sobre el estado de la salud publica: una perspectiva desde los Estados Unidos. In: La Crisis de la Salud
Publica: Reflexiones Para el Debate. Washington D.C.: PAHO; 1992, p. 133-147. Translated into English: On the
status of public health: a view from the United States. In: The Crisis of Public Health: Reflections for the Debate.
Washington D.C.: PAHO, 1992, p. 121-135.
145.
Omenn GS. Methods and approaches for monitoring exposures to hazardous substances and their effects. In: Lykke E,
ed. Achieving Environmental Goals: The Concept and Practice of Environmental Performance Review. London, United
Kingdom, Pinter Publishers; 1992, p. 86-100.
146.
Omenn GS. Policy aspects of epidemiologic studies of possible health effects of electric and magnetic fields from power
lines. Public Health Rev 1991/92; 19:35-38.
147.
Omenn GS. Population and environment: core issues for PSR's agenda on peace and security. PSR Quarterly 1993; 3:811.
148.
Omenn GS. Environmental biotechnology: biotechnology solutions for a global environmental health problem, hazardous
chemical wastes. In: Huang PC, Lin RS, Chow LP, editors. Research in Human Capital and Development: Health Care in
the Changing Economic and Social Environment; 1993; 7:273-283.
Omenn GS. Commentary: The role of environmental epidemiology in public policy. Annals of Epidemiology 1993;
3:319-322.
149.
150.
Omenn GS. Preface to Volume 14. In: Omenn GS, Fielding JE, Lave LB. Ann Rev Public Health 1993; 14:v-vi.
151.
Omenn GS. Environmental biotechnology: biotechnology solutions for a global environmental health problem, hazardous
chemical wastes. Asia-Pacific Journal of Public Health, 1993; 6:40-45.
152.
Omenn GS. Can Lawyers and Scientists Get Along? Special Supplement, Law Practice in the 90s, The Seattle Daily
Journal of Commerce, June 16, 1993, p. 2.
153.
Omenn GS. Commentary: Challenges facing public health policy. J Amer Dietetic Assn, June, 1993; 93:643.
154.
Brandt EN Jr., Omenn GS. Preface to Improving Toxicology & Environmental Health Information Services: Long
Range Plan. U.S. Department of Health & Human Services, National Institutes of Health, National Library of Medicine
Long Range Planning Panel on Toxicology and Environmental Health; September 1993 Report of the Board of Regents,
p. 7.
155.
Costa LG, Omiecinski CJ, Faustman EM, Omenn GS. Ecogenetics:determining susceptibility to chemical-induced
diseases. Washington Public Health, 1993; 11:8-11.
156.
Omenn GS, Oberle M, Gale J, Hoover JJ, Sandlin D, Tapp J. Notes from the Field: The Northwest Center for Public
Health Practice. Am J Public Health, 1993; 83:1788-1789.
157.
Omenn GS. Introduction to section on Testing and Determination of Property Rights. The scope and value of patent
protection. In: Frankel MS, Teich A, editors. 1992 AAAS/ABA Conference on Frontier Issues in Ethics, Law and
Testing. The Frontier: Ethics, Law, and Policy. AAAS Press; 1994, p. 177-179.
158.
Omenn GS. Preface to Volume 15. In: Omenn GS, Fielding JE, Lave LB. Ann Rev Public Health 1994; 15:v-vi.
159.
Omenn GS. Public health careers in the era of health reform. Washington State Public Health Association Newsletter;
Winter 1994, p. 6.
160.
Omenn GS. Reactions of the public health community to the Clinton Health Care Reform Plan. Leadership in Public
Health 1994; 3:13-14.
161.
Omenn GS. Enhancing the role of the scientific expert witness. Environ Health Persp 1994; 102:674-675.
162.
Omenn GS. Don't forget community public health services in the debate on health. The Washington Post; August 2,
1994, p. C5.
163.
Omenn GS. Prevention: What does it save? What does it Cost? Prevention: Benefits, Costs, & Savings. A report
prepared for Partnership for Prevention. Washington, D.C.: Partnership for Prevention, 1994; 1-8.
164.
Omenn GS. Ames test. In: Eblen RA, Eblen WR, editors: The Encyclopedia of the Environment. New York: Houghton
Mifflin Company; 1994:p.11.
165.
Omenn GS. Environmental biotechnology. In: Eblen RA, Eblen WR, editors: The Encyclopedia of the Environment.
New York: Houghton Mifflin Company; 1994:70.
166.
Omenn GS. Public health. In: Eblen RA, Eblen WR, editors: The Encyclopedia of the Environment. New York:
Houghton Mifflin Company; 1994:581-583.
167.
Omenn GS. Progress in science-based risk assessment and risk management. Technology: Journal of the Franklin
Institute. 1994; 331A:21-27.
168.
Omenn GS. Prevention policy: perspectives on the critical interaction between research and policy. Presented at NIH
Conference on Disease Prevention Research at NIH: an Agenda for All, October 6, 1993, Bethesda, MD. Prev Med 1994;
23:612-617.
169.
Omenn GS. Can systematic, integrated risk assessment with full stakeholder participation enhance cleanup at DOE's
sites? In: Gee GW, Wing R, editors: The 1994 Herbert H. Parker Lecture presented at the Thirty-Third Hanford
Symposium on Health and the Environment. In-situ remediation: scientific basis for current and future technologies.
Battelle Press; 1994, Part I: xv-xxx.
170.
Omenn GS. The context for a future school of public health committed to urban health needs. In: Hogness J,
McLaughlin C, Osterweis M, editors: The University in the Urban Community: Responsibilities for Public Health.
Washington, D.C.: Association of Academic Health Centers; 1995;93-116.
171.
Omenn GS. Preface to Volume 16. In: Omenn GS, Fielding JE, Lave LB. Ann Rev Public Health 1995; 16:v-vi.
172.
Roe D, Omenn. GS. California has successful model of regulatory risk assessment. Op-ed. Seattle Post-Intelligencer,
1995;A9.
173.
Omenn GS. What accounts for the association of vegetables and fruits with lower incidence of cancers and coronary
heart disease? (Invited editorial). Annals of Epidemiology 1995; 5:333-335.
174. Fields ML, Omenn GS. 25 years of challenges and successes in public health. Washington Public Health 1995; 13:1,7.
175.
Cassel CK, Omenn GS. Dimensions of care of the dying patient. In: Cassel CK, Omenn GS, editors: Caring for Patients
at the End of Life. West J Med 1995; 163: 224-225. [Cassel CK, Omenn GS, editors. Caring for Patients at the End of
Life. West J Med 1995; 163:197-318.]
176.
Omenn GS. Assessing the risk assessment paradigm. EPA/HERL Symposium, November, 1993, Research Triangle Park,
N.C. Toxicology 1995; 102:23-28.
177.
Omenn GS. Testing and screening: Predictive testing in the workplace. In: Reich WT, editor: Encyclopedia of Bioethics.
New York: Simon & Schuster Macmillan; 1995; 2:995-1000.
178.
Omenn GS, Motulsky, AG. Genetics and environment in human health. In: Reich WT, editor: Encyclopedia of Bioethics.
New York: Simon & Schuster Macmillan; 1995; 2:940-946.
179.
Faustman EM, Omenn GS. Risk assessment. In: Klaassen CD, editor. Casarett and Doull’s Toxicology: The Basic
Science of Poisons. Chapter 4. New York, NY, McGraw-Hill; 1996:75-88.
180.
Omenn GS. Proposition 65: finding common ground in environmental health regulation. Health & Environment Digest
1996; 9(11):95-97.
181.
Omenn GS. Perspectives Beyond Health Promotion: CDC/Prevention Center Linkages. Amer J Health Promotion 1996;
5:92-93.
182.
Omenn GS. Cancer Prevention. In: Bennett JC, Plum F, editors. Cecil Textbook of Medicine, 20th ed. Philadelphia, PA,
W.B. Saunders; 1996:1008-1010.
183.
Omenn GS. Variation in susceptibility as a key parameter in risk assessment and risk communication: policy aspects. In:
Walker C, Groopman J, Slaga TJ, Klein-Szanto A, editors. Susceptibility: Impact on Risk Assessment. Progress in
Clinical and Biological Research, Vol.395, New York: Wiley Liss; 1996:235-247.
184.
Omenn GS. Preface to Volume 17. In: Omenn GS, Fielding JE, Lave LB, editors. Ann Rev Public Health 1996; 17: v-vii.
185.
Gordon RL, Baker EL, Roper WL, Omenn GS. Prevention and the reforming U.S. health care system: Changing roles
and responsibilities for public health. Ann Rev Public Health 1996; 17:489-509.
186.
Omenn GS. Genetic monitoring and profiling for the workplace. In: Blank RH, Merrick JC, editors. Encyclopedia of
U.S. Biomedical Policy. Westport, Connecticut, Greenwood Press; 1996:104-108.
187.
Omenn GS. Making use of cancer risk assessment. Issues in Science and Technology 1996; 12:29.
188.
Omenn GS. Risk assessment and risk management: report on the presidential/congressional risk commission. In:
National Forum on Science and Technology Goals: Linking Science and Technology to Society’s Environmental Goals.
Washington, D.C. National Academy Press; 1996:449-461.
189.
Omenn GS. Putting environmental risks in a public health context. Public Health Reports 1996; 111:514-516.
190.
Omenn GS. Risk assessment for butadiene: introductory and summary comments. International Congress of Toxicology
International Symposium: Evaluation of Butadiene & Isoprene Health Risks. Toxicology 1996; 113:
5-11.
191.
Omenn GS, Faustman EM. Risk assessment, risk communication, and risk management. Detels R, Holland W, McEwen
J, Omenn GS, editors. Oxford Textbook of Public Health. 3rd Ed., Volume 2, Oxford University Press; 1997:969-986.
192.
Omenn GS. Genetics and public health. Am J Public Health 1996; 86:1701-1703.
193.
Boiko PE, Morrill RL, Flynn J, Faustman EM, van Belle G, Omenn GS. Who holds the stakes? A case study of
stakeholder identification at two nuclear weapons production sites. Risk Analysis 1996; 16: 237-249.
194.
Omenn GS. Response to Letters: Antioxidant vitamins, cancer, and cardiovascular disease. New Engl J Med 1997;
335:1067-1068.
195.
Omenn GS, Beresford SAA, Buchner DM, LaCroix A, Martin M, Patrick DL, Wallace JI, Wagner EH. Evidence of
modifiable risk factors in older adults as a basis for health promotion/disease prevention programs. In: T Hickey, M
Speers, T Prohaska, eds. Public Health and Aging. Chapter 7. Baltimore, MD, Hopkins University Press; 1997: 107127.
196.
Deyo RA, Psaty BM, Simon G, Wagner EH, Omenn GS. The messenger under attack-- Intimidation of researchers by
special-interest groups. New Engl J Med 1997; 336:1176-1180.
197.
Beresford SAA, Motulsky AG, Omenn GS, Boushey CJ. Response to Letters: Folic acid and food fortification. JAMA
1997; 275:682-683.
Omenn GS. Insights from the Risk Commission. Risk Policy Report March 1997; 31-33.
198.
199.
Omenn GS and CARET Co-authors. Response to letter to the editor; Risk factors for lung cancer and intervention effects
in CARET. JNCI 1997; 89:325-326.
200.
Omenn GS, Thornquist MD. Response to letter to the editor; -carotene and the risk of lung cancer. JNCI 1997; 89:457458.
201.
Charnley G, Omenn GS. A summary of the findings and recommendations of the Commission on Risk Assessment and
Risk Management. In: Human and Ecological Risk Assessment. Boca Raton, FL:CRC Press LLC, 1997; Vol. 3: 701711.
202.
Ohanian EV, Moore JA, Fowle III JR, Omenn GS, Lewis SC, Gray GM, North DW. Risk characterization: A bridge in
informed decision making. Fundamental and Applied Toxicology 1997; 39:81-88.
203. Omenn GS. Chemoprevention of lung cancer: the rise and demise of beta carotene. Annual Rev Public Health 1998;
19:73-99.
204. Omenn GS. Highlighting Environmental Health in Turning Point. Transformation in Public Health 1998;1(2):1-2,13.
205. Omenn GS. The implications of genetic advances for future care. Proc of the Academic Health Centers’ 5th Congress of
Health Professions Educators, Washington DC, June 18-19, 1998:1-13.
206. Eaton, DL, Farin F, Omiecinski CJ, Omenn GS. Genetic susceptibility. In: William N. Rom, ed. Environmental &
Occupational Medicine, 3rd edition. Philadelphia: Lippincott-Raven, 1998:209-221.
207. Omenn GS. An assessment of the scientific basis for attempting to define the Dietary Reference Intake for beta carotene.
J Amer Dietetic Assn 1998;98(12):1406-1409.
208
Omenn GS. Health status and its determinants in urban populations. J Urban Health 1998 Jun;75(2):219-227.
209.
Omenn GS. Regulatory affairs; regulatory frameworks and decisions matter to the development of biotechnology and the
approvals for biotechnology products. Editorial Overview, Curr Opin Biotech 1999;10:287-288.
210.
Omenn GS. Perspectives of public health. In: M Hager (ed.), Education for More Synergistic Practice of Medicine and
Public Health. New York, Josiah Macy, Jr. Foundation 1999:34-40.
211.
Omenn GS. Caring for the community: The role of partnerships. AAMC Robert G. Petersdorf Lecture. Academic
Medicine 1999;74 (7):782-789.
212.
Omenn GS, Clark NM. The Guide to Community Preventive Services will be influential in academic health centers:
education, research, and links with practice. Amer J Prev Med 2000; 18:12-14.
213.
Omenn GS. Cancer Prevention, Chapter 190. In Cecil Textbook of Medicine, 21 st edition. Goldman L and Bennett JC,
(eds.). Philadelphia: WB Saunders, 2000:1032-1035.
214.
Omenn GS, Lichter AS, Warren L and Bollinger LC. Shaping a positive future for academic medicine at Michigan.
JAMA 2000;283:927-928.
215.
Omenn GS. The genomic era: a crucial role for the public health sciences. Environ Health Perspectives 2000;108:
160-161.
216.
Omenn, GS. Public Health Genetics: an emerging interdisciplinary field for the post-genomic era. Annual Rev Pub
Health 2000;21:1-13.
217.
Bartell SM, Takaro TK, Ponce RA, Hill JP, Faustman EM, Omenn GS. Risk assessment and screening strategies for
beryllium exposure. Technology 2000;7:241-249.
218.
Omenn GS, Warren L. Putting patients and families first. Michigan Health & Hospitals July/Aug 2000; 36(4):
38-39.
219.
Omenn GS. Chemoprevention of lung cancer is proving difficult and frustrating, requiring new approaches. JNCI
2000;92(12): 959-960.
220. Omenn GS. Federal policy making for biotechnology executive branch office of management and budget.
Murray, TJ, Mehlman, MJ (eds.) In: Encyclopedia of Ethical, Legal, Policy Issues in Biotechnology. John Wiley &
Sons, Inc.; 2000: 257-262.
221.
Omenn GS. Genetics and public health: Historical perspectives and current challenges and opportunities.
Khoury MJ, Burke W, Thomson EJ (eds.). In: Genetics and Public Health in the 21 st Century: Using Genetic
Information to Improve Health and Prevent Disease, Chapter 2. New York: Oxford University Press, 2000:
25-44.
222. Omenn GS. Prospects for pharmacogenetics and ecogenetics in the new millennium. Drug Metabolism and
Disposition 2001;29: 611-614.
223.
Omenn GS. Homocysteine as a risk factor in atherosclerotic cardiovascular disease. In: Ernst CB, Stanley (eds), Current
Therapy in Vascular Surgery, 4th ed., St. Louis, MO: Mosby, 2001:355-359.
224.
Omenn GS: The new millennium: Values, perceptions of risk, and the key roles of science and technology. Health
Physics, April 2001, 80(4): 328-332.
225.
Baker JR, Omenn GS. Practical plan can deter bioterrorism. Commentary, The Detroit News, October 10, 2001.
226.
Faustman EM, Omenn GS. Risk assessment. In: Klaassen CD (ed.), Casarett and Doull’s Toxicology: The Basic
Science of Poisons, New York: McGraw-Hill, 2001:83-104.
227.
Omenn, GS. Environmental biotechnology; Public health. In:Eblen RA, Eblen WR (eds), The Environment
Encyclopedia, Tarrytown NY: Marshall Cavendish, 2001, vol. 2, p. 135 and vol. 8, pp. 1028-1033.
228.
Omenn GS. Special challenges in applying genomics to population health. J Biolaw & Bus, Global Genomics and
Health Disparities, Special Supplement 2001:3-6.
229.
Omenn GS. Assessment of human cancer risk: challenges for alternative approaches. Toxicologic Pathology, 2001,
29 (Suppl.):5-12.
230. Omenn GS, Faustman EM. Risk assessment and risk management. In Detels R, McEwen J, Beaglehole R, Tanaka
H, eds. Oxford Textbook of Public Health. Chapter 8.8. 4 th Ed., Volume 2. New York: Oxford University Press,
2002:1083- 1103.
231. Omenn GS. Genetic advances will influence the practice of medicine: Examples from cancer research and care of
cancer patients. Genetics in Medicine 2002; 4(6), Supp: 15S-20S.
232. Omenn GS. The crucial role of public health sciences in the postgenomic era. Genetics in Medicine 2002; 4(6),
Supp: 21S-26S.
233. Nallamothu BK, Fendrick M, Omenn GS. Homocyst(e)ine and coronary heart disease. PharmacoEconomics
2002; 20:429-442.
234. Omenn GS, Motulsky AG. Integration of pharmacogenomics into medical practice. In Rothstein MA (ed.),
Pharmacogenomics: Social, Ethical, and Clinical Dimensions, John Wiley & Sons, Inc., 2003:137-162.
235. Coplon-Newfield G, Omenn G. U.S. use of landmines would be a mistake. Commentary. The Detroit News,
January 10, 2003.
236
Oakley G, Wald N, Omenn G. Provide the citizens of New Zealand the miracle of folic acid fortification. New
Zealand Med J 2003; 116:1168. Available from: http://www.nzma.org.nz/journal/116-1168/302/
237
Omenn GS. A Better Medicare for Healthier Seniors: Recommendations to Modernize Medicare’s Prevention
Policies. Historical and current policy issues in establishing coverage for clinical preventive services under
Medicare. Partnership for Prevention, Washington, DC. 2003:13-34.
238. Omenn GS. Science and Technology Policies Concerning the Life Sciences. In Teich AH, Nelson SD, Lita SJ (ed 2003
AAAS Science & Technology Yearbook, Washington DC: American Association for the Advancement of
Science, chapter X (http://www.aaas.org/spp/rd/pubs.htm).
239. Schwarz JJH, Omenn GS. Op-Ed: Taking on mercury pollution. State’s head-on approach will help phase out
mercury emissions. Detroit Free Press, 15 December, 2003.
240. Omenn, GS. On the significance of “The Red Book” in the evolution of risk assessment and risk management.
Human and Ecological Risk Assessment, 2003, 9:1155-1167.
241. Omenn GS. Cancer Prevention, chapter 190. In Cecil Textbook of Medicine. 22 nd ed, Goldman L & Ausiello D
(eds). Philadelphia, PA: W.B. Saunders, 2004, pp. 1134-1137.
242. Omenn GS. International collaboration in clinical chemistry and laboratory medicine: the Human Proteome
Organization (HUPO) Plasma Proteome Project. Clin Chem Lab Med, 2004; 42:1-2.
243. Omenn GS. The Human Proteome Organization Plasma Proteome Project Pilot Phase: Reference Specimens,
Technology Platform Comparisons, and Standardized Data Submissions and Analyses. Proteomics. 2004 May;4:1235-40.
244. Omenn, GS. Human lung cancer chemoprevention strategies: Parker B. Francis lecture. Chest. 2004 May;125
(5 Suppl):123S-7S.
245. Coffield AB, Omenn GS, Fielding JE, Long PV, Kamerow DB. The camel’s nose is under the tent: opportunities for
prevention associated with the 2003 Medicare Act. AJPM. 2004 May; 26;4:375-6.
In Press
Adamski M, States DJ, Omenn GS. Data standardization and integration in collaborative proteomics studies.
In Srivastava S (ed). Informatics in Proteomics. New York, Marcel Dekker, Inc., 2004;Chapter 8.
Alfano CM, Klesges RC, Murray DM, Bowen DJ, McTiernan A, Vander Weg MW, Robinson LA, Cartmel B, Thornquist MD,
Barnett M, Goodman GE, Omenn GS. Physical activity in relation to all-site and lung cancer incidence and mortality in current
and former smokers. Cancer Epidemiology, Biomarkers, and Prevention, in press.
Cullen M, Barnett M, Balmes J, Cartmel B, Redlich C, Brodkin C, Barnhart S, Rosenstock L, Goodman G, Hammar S,
Thornquist M, Omenn GS. Predictors of lung cancer among asbestos-exposed men in the β-carotene and retinol efficacy trial.
American Journal of Epidemiology, in press.
Books
1.
Seixas FA, Omenn GS, Burke ED, Eggleston SA, editors. Nature and Nurture in Alcoholism. Ann NY Acad Sci 1972, v.
197, 229 pp.
2.
Ehrman L, Omenn GS, Caspari E, editors. Genetics, Environment and Behavior: Implications for Educational Policy.
New York: Academic Press, 1972, 324 pp.
3.
Lave L, Omenn GS. Clearing the Air: Reforming the Clean Air Act. Washington, DC: Brookings Institution, 1981.
p. 51 Extracts: Op-ed, Washington Post, 29 Nov. 1981, p. C5; The Brookings Bulletin, Fall 1981, p. 5-7; Op-ed,
Los Angeles Time, 7 Feb. 1982, p. IV-5; Newsletter, Federation of American Scientists Public Interest Report, Mar.
1982; 35:7-8
4.
Omenn GS, Hollaender A, editors. Genetic Control of Environmental Pollutants. New York: Plenum Press, 1984,
408 pp.
5.
Omenn GS, Gelboin HV, editors. Banbury Report 16. Variability in Responses to Chemical Exposures. Cold Spring
Harbor: Cold Spring Harbor Laboratory, 1984, 400 pp.
6.
Omenn GS, Teich AH, editors. Biotechnology and the Environment. New Jersey: Noyes Data Corporation, 1986,
169 pp.
7.
Omenn GS, editor. Environmental Biotechnology: Reducing Risks from Environmental Chemicals through
Biotechnology. [Basic Life Sciences, 45] New York: Plenum Press, 1988, 505 pp.
8.
Kamely K, Chakrabarty A, Omenn GS, editors. Biotechnology and Biodegradation. The Woodlands, Texas: Portfolio
Publishing Company, [Advances in Applied Biotechnology series, 4] 1990, 504 pp.
9.
Cantor C, Caskey T, Hood L, Kamely D, Omenn GS, editors. Biotechnology and Human Predisposition to Disease. New
York: Wiley-Liss Inc, 1990, v.126, 241 pp.
10.
Omenn GS, Fielding JE, Lave LB, editors. Annual Review of Public Health. Palo Alto: Annual Reviews Inc., 1991, v.
12, 585 pp.
11.
Omenn GS, Larson EB, Wagner EH, Abrass I, editors. Health Promotion and Disease Prevention. Clinics in Geriatric
Medicine. Philadelphia: W.B. Saunders Company, 1992, 233 pp.
12.
Omenn GS, Fielding JE, Lave LB, editors. Annual Review of Public Health. Palo Alto: Annual Reviews Inc., 1992, v.
13, 552 pp.
13.
Omenn GS, Fielding JE, Lave LB, editors. Annual Review of Public Health. Palo Alto: Annual Reviews Inc., 1993, v.
14, 689 pp.
14.
Omenn GS, Fielding JE, Lave LB, editors. Annual Review of Public Health. Palo Alto: Annual Reviews Inc., 1994, v.
15, 595 pp.
15.
Omenn GS, Fielding JE, Lave LB, editors. Annual Review of Public Health. Palo Alto: Annual Reviews Inc., 1995, v.
16, 514 pp.
16.
Fielding JE, Lave LB, editors. Annual Review of Public Health. Palo Alto: Annual Reviews Inc., 1996, v. 17, 559 pp.
17.
Detels R, Holland W, McEwen J, Omenn GS, editors. Oxford Textbook of Public Health, 3rd Ed. Oxford University
Press, 1997, volumes 1-3, 1651 pp.
Book Reviews
1.
Omenn GS. Am J Hum Genet 1971; 23:331-332. Behavior Genetics: The Mouse as a Prototype. Lindzey G, Thiessen Dd
(eds.). New York: Appleton-Century-Crofts, Inc. 1970, 336 pp.
2.
Omenn GS. Am J Hum Genet 1972; 24:487. Genetic Disorders of the Endocrine Glands. DL Rimoin and RN Schimke.
Saint Louis: C V Mosby Cp. 1971, 383 pp.
3.
Omenn GS. Am J Hum Genet 1972; 24:705-706. An Introduction to the Study of Man. JZ Young. Oxford: Clarendon
Press 1971, 719 pp.
4.
Omenn GS. Am J Hum Genet 1973; 25:461-462. Factors in "Schizophrenia." Kaplan AR (ed.). Springfield IL: Charles
C. Thomas 1972, 698 pp.
5.
Omenn GS. Am J Hum Genet 1974; 26:666. Biology of Brain Dysfunction. Gaull GE (ed.). New York: Plenum Press
1973, 403 pp.
6.
Omenn GS. Am J Hum Genet 1975; 27:257-258. Serotonin in Down's Syndrome. Coleman M (ed.). New York:
American Elsevier Publishing Co. 1973, 224 pp.
7.
Omenn GS. Am J Hum Genet 1976; 28:89-90. Psychology of sex differences in men and women. Males and Females. C
Hutt. London: Penguin Books 1972, 158 pp.; Gender Differences: Their Ontogeny and Significance. Ounsted C, Taylor
Dc (eds.). Baltimore: Johns Hopkins University Press 1972, 273 pp.; Man & Woman, Boy & Girl. J Money and AA
Ehrhardt. Baltimore: Johns Hopkins University Press 1972, 311 pp., The Psychology of Sex Differences. MacCoby EE,
Jacklin CN. Stanford CA: Stanford University Press 1974, 634 pp.
8.
Omenn GS. Behavioral Teratology Newsletter I:5-6, 1976. Drug Effects on the Fetus.
A Survey of the Mechanisms
and Effects of Drugs on Embryogenesis and Fetogenesis. H Tuchmann-Duplessis. Sydney, Australia: ADIS Press &
Publishing Sciences Group1975, 267 pp.
9.
Omenn GS. Am J Hum Genet 1977; 29:115-116. Is Alcoholism Hereditary? D Goodwin, New York: Oxford University
Press 1976, 171 pp.
10.
Omenn GS. Social Science and Medicine II:138, 1977. Health Services for Tomorrow: Trends and Issues. EM Burns.
New York: Dunellen Publishing 1973, 226 pp.
11.
Omenn GS. Am J Hum Genet 1979; 31:90-91. Psychiatry and Genetics: Psychosocial, Ethical, and Legal Considerations.
Sperber MA, Jarvik LF (eds.). New York: Basic Books 1976, 204 pp.
12.
Omenn GS. Am J Hum Genet 1979; 31:389-390. Inheritance of Creative Intelligence. J Karlsson. Chicago: Nelson Hall
1978, 206 pp.
13.
Omenn GS. Medical Care 1980; 18:251-252. The Politics of Health Care. JHU Brown. Cambridge MA: Ballinger
Publishing Company 1980, 146 pp
14.
Omenn GS. Regulating health care: the struggle for control. Proc of the Academy of Political Science, Vol 33. Levin A
(ed.). New York: The Academy of Political Science 1980.
15.
Omenn GS. Am J Hum Genet 1982; 34:676-677. Is Science Sexist? Ruse M. Boston, MA: D. Reidel Pub Co. 1981, 299
pp.
16.
Omenn GS. Am J Hum Genet 1983; 35:325-326. Violence and the Politics of Research. Gaylin W, Macklin R, Powledge
TM (eds.), New York: Plenum Press 1981, 256 pp.
17.
Omenn GS. Molecular neurobiology. Science 1983; 220:40l. Molecular Approaches to Neurobiology. Brown IR (ed.),
New York: Academic Press 1982, 422 pp.
18.
Omenn GS. N Engl J Med; 1983; 309:674-675. Genetics of Neurological and Psychiatric Disorders. Kety SS, Rowland
L, Sidman RL, Matthysse SW (eds.). New York: Raven Press1983, 300 pp.; The genetics of Neurological Disorders. M
Baraister, New York: Oxford Univ Press 1982, 516 pp.
19.
Omenn GS. Health policy. Issues in Science and Technology, Fall 1985, Vol 2, 1:152-153. Review of the Public Health
Service's Response to Acquired Immune Deficiency Syndrome. Office of Technology Assessment, Washington DC:
U.S. Congress, February 1985, 158 pp.
20.
Omenn GS. Health policy. Issues in Science and Technology, Winter 1986, Vol 2, 2:136-185. Physicians and Hospitals:
The Great Partnership at the Crossroads. Yaggy D, Hodgson P (eds.). Durham NC: Duke Univ Press
1985, 202 pp.
21.
Omenn GS. Health policy. Issues in Science and Technology, Spring 1986, Vol 2, 3:133-136. Prescription for Change:
Report of the Task Force on Academic Health Centers. Commonwealth Fund. New York: Harkness House
1985, 151 pp.
22.
Omenn GS. Health policy. Issues in Science and Technology, Summer 1986, Vol 2, 4:112-115. A Case Study of United
Healthcare: Lessons for Health Care Plans. Martin DP, Ehreth JL, Geving AR (eds.), Menlo Park CA: Henry J. Kaiser
Family Foundation 1985, 175 pp.
23.
Omenn GS. Health policy. Issues in Science and Technology, Fall 1986, Vol 3, 1:117-120. For-Profit Enterprise in
Health Care. Institute of Medicine, Washington DC: National Academy Press 1986, 556 pp.
24. Omenn GS. Health policy. Issues in Science and Technology, Winter 1987, Vol 3, 2:119-122 Women and Children Last:
The Plight of Poor Women in Affluent America. R Sidel, New York: Viking Press 1986, 236 pp.; Monitoring Children's
Health: Key Indicators. C Miller, A Fine, S Adams-Taylor, LB Schorr. Washington DC: American Public Health Assoc
1986, 124 pp.; Maternal and Child Health Data Book: The Health of America's Children. D Hughes, K Johnson, J
Simons, S Rosenbaum. Washington DC: The Children's Defense Fund 1986, 302 pp.
25.
Omenn GS. Health policy. Issues in Science and Technology, Spring 1987, Vol 3, 3:118-120. Improving the Quality of
Care in Nursing Homes. Institute of Medicine, Washingotn DC: National Academy Press 1986: 415 pp.
26.
Omenn GS. Health policy. Issues in Science and Technology, Summer 1987, Vol 3, 4:111-113. The Health Economy.
Fuchs VR (ed.), Cambridge MA: Harvard Univ Press 1986, 401 pp.
27.
Omenn S. Health policy. Issues in Science and Technology, Fall 1987, Vol 4, 1:99-101. Pain and Disability: Clinical,
Behavioral, and Public Policy Perspectives. Osterweis M, Kleinman A, Mechanic D (eds.), Institute of Medicine
Committee on Pain, Disability, and Chronic Illness Behavior, Washington DC: National Academy Press 1987, 306 pp.
28.
Omenn GS. Health policy. Issues in Science and Technology, Winter 1988, Vol 4, 2:113-115. Adding Life to Years:
Organized Geriatrics Services in Great Britain and Implications for the United States. Barker WH. Baltimore: Johns
Hopkins Univ Press 1987, 237 pp.
29.
Omenn GS. Health policy. Issues in Science and Technology, Spring 1988, Vol 4, 3:102-104. Ourselves, Growing Older:
Women Aging with Knowledge and Power. Doress PB, Siegal DL and the Midlife and Older Women Book Project of the
Boston Women's Health Book Collective. New York: Simon & Schuster 1987; 511 pp; Your Good Health: How to Stay
Well, and What to Do When You're Not. Bennett WI, Goldfinger SE, Johnson GT (eds.), Cambridge, MA: Harvard Univ
Press 1987, 510 pp.
30.
Omenn GS. Issues in Science and Technology, Summer 1988, Vol 4, 4:98-100. Ethical Dilemmas in Health Promotion.
Doxiadis S (ed.), New York: John Wiley & Sons 1987; 234 pp; The Health of Nations: True Causes of Sickness and
Well-Being. Sagan LA(ed.), New York: Basic Books 1987; 233 pp; Corporate Physicians: Between Medicine and
Management. Wash DC. New Haven: Yale Univ Press 1987, 267 pp.
31.
Omenn GS. Issues in Science and Technology, Fall 1988, Vol 5,1:104-106; Human Organ Transplantation: Societal,
Medical-Legal, Regulatory, and Reimbursement Issues. Cowan DH, Kantorowitz JA, Moskowitz J, Rheinstein PH
(eds.)Ann Arbor MI: Health Administration Press 1987; 458 pp.; Transplantation in New York State: The Procurement
and Distribution of Organs and Tissues. New York State Task Force on Life and the Law;Life-Sustaining Treatment:
Making Decisions and Appointing a Health Care Agent. New York State Task Force on Life and the Law, New York
1988, 164 pp.
32.
Omenn GS. Issues in Science and Technology, Winter 1989, Vol 5, 2:105-106. The Future of Public Health by a panel of
the Institute of Medicine. Washington DC: National Academy Press 1988, 218 pp.
33.
Omenn GS. Issues in Science and Technology, Spring 1989, Vol 5, 3:111-112. Physician Payment Review Commission,
Second Annual Report to Congress, Washington DC: US Govt Printing Office, 1988; A National Study of ResourceBased Relative Value Scale for Physician Services: Final Report to the Health Care Financing Administration. Hsiao WC,
Braun P, Becker ER (eds.), Boston: Harvard Univ Press 1988.
34.
Omenn GS. J Natl Cancer Inst 1989; 81:1748-49. Advances in Cancer Control:Innovations and Research. Anderson PN,
Engstrom PF, Mortenson LE (eds.), New York: Alan R. Liss, 1989, 84 pp.
35.
Omenn GS. Am J Hum Genet 1990; 46:1006-1007. Proceed With Caution: Predicting Risks in the Recombinant DNA
Era. Holtzman NA (ed.), Baltimore: Johns Hopkins Univ Press, 1989, 303 pp.
36.
Omenn GS. JMAM 1990; 264:3201. For the Health of a Nation: A Shared Responsibility. Report of the National
leadership Commission on Health Care. Ann Arbor, MI: Health Administration Press, 1989, 206 pp.
37.
Omenn GS. Public health, primary care. JAMA 1993; 269:2560-2561. Healing the Schism: Epidemiology, Medicine, and
the Public's Health. White KL, New York: Springer-Verlag, 1991.
38.
Omenn GS. Am J Prev Med 1993; 9:324. Setting Domestic Priorities: What Can Government Do? Aaron HJ,
Schultze CL (eds.), Washington DC: Brookings Institution, 1992, 318 pp.
39.
Omenn GS. Am J Hum Genet 1995; 56:548. Target Organ Toxicology Series. Hayes W, Thomas JA, Gardner DE (eds.),
New York: Raven Press, 1994, 496 pp.
40.
Omenn GS. Illahee, 1995, Vol 11, 3 & 4:217-218. Risk, Science, and Politics: Regulating Toxic Substances in Canada
and the United States. K Harrison, G Hoberg, (eds.), Montreal: McGill-Queens Univ Press, 1994; 235 pp; Environmental
Health Risks and Public Policy: Decision-Making in Free Societies. DV Bates (ed.), Univ of Washington Press, 1994,
117 pp.
41.
Omenn GS. Quarterly Review of Biology 1996;71:612-613. Review of Regulatory Toxicology. Chengelis CP, Holson
JF, Gad SC (eds.), New York: Raven Press, 1995, 239 pp.
42.
Omenn GS. Issues in Science and Technology, Fall, 1997, Vol 14, 1:93-96. Pesticides: kids at risk. Our
Children’s Toxic Legacy: How Science and Law Fail to Protect Us From Pesticides. John Wargo. New Haven,
CN: Yale University Press, 1996, 380 pp.
43.
Omenn GS. Poverty and disease. JAMA 1998;280:2131. Stunted Lives, Stagnant Economies: Poverty, Disease, and
Underdevelopment. E Stillwagon (ed.), New Brunswick NJ: Rutgers University Press, 1998, 342 pp.
44.
Omenn GS. Public Health Reports 2001; 116: 176-178. Promoting Healthy Behavior: How much freedom? Whose
responsbility? Daniel Callahan (ed.), Washington, DC: Georgetown University Press, 2000, 192 pp.
45.
Omenn GS. Protecting America’s Health: The FDA, Business, and One Hundred Years of Regulation, Hilts PJ. Alfred
A. Knopf, New York, 2003 394 pp. A scientific basis for safety. Nature Medicine, 2004;10:8;773.
46.
Omenn, GS. Advances in Protein Chemistry, Proteome Characterization and Proteomics. Hamadeh H, Afshari C, (eds),
Hoboken: Wiley-Liss, 2004, 361 pp. Toxicogenomics: Principles and Applications. Environmental Health
Perspectives, 2004.
Published Abstracts
1.
Gill TJ III, Omenn GS. Studies on the structure of polylysine in solution. Amer Chem Soc Mtg, Atlantic City, NJ,
September 13-17, 1965.
2.
Gill TJ, Omenn GS. Effects of temperature and viscosity on the polarization of fluorescence of synthetic polypeptide-dye
conjugates. Fed Proc 1966:789.
3.
Omenn GS. Structure and function relationships in staphylococcal nuclease. Mid-Atlantic Amer Chem Soc Mtg,
Washington, February 12-15, 1969.
4.
Omenn GS. Parathyroid hormone production by malignant tumors of non-parathyroid origin. Fourth Ann Pub Hlth Serv
Clin Soc Mtg, Boston, MA, June 2-5, 1969.
5.
Omenn GS. Isolation of mutants of Staphylococcus aureus lacking extra-cellular nuclease activity. Genetics 1969; 61:
544-545.
6.
Omenn GS. Yoshida A. Specific isolation of proteins of interest by affinity and elution chromatography. Ann Meet of the
Canadian Genet Soc, Vancouver, BC, May 13-15, 1970. Canad J Genet Cytol 1970; 12:391.
7.
Omenn GS. Non-random derepression in the ectopic production of polypeptide hormones by human tumors. Genetics
1970; 64:548.
8.
Cohen PTW, Omenn GS, Motulsky AG. Enzyme polymorphisms as markers for brain metabolism. Amer J Hum Genet
1970; 24:46a.
9.
Omenn GS, Motulsky AG. Perspectives for analysis of normal and abnormal behavior in man. Soc Biol 1971; 18:316.
10.
Omenn GS, Cohen PTW, Motulsky AG. Genetic variation in glycolytic enzymes in human brain. 4th Intl Cong Hum
Genet, Paris, September 6-11, 1971.
11.
Omenn GS. Studies of serum thyroxine-binding globulin (TBG). In: McKusick VA, editor. Third Conf on Clin
Delineation of Birth Defects. 1971. Birth Defects Orig Article Series VII (8):196.
12.
Omenn GS. Familial reticuloendotheliosis with eosinophilia. A follow-up. In: McKuskick VA, ed. Third Conf on Clin
Delineation of Birth Defects. 1971. Birth Defects Orig Article Series VII (8):196.
13.
Palmieri GMA, Nordquist RE, Omenn GS. Intracellular localization of ectopic parathyroid hormone in human tumors. 4th
Intl Cong Endocrinology, Washington, DC, June 24, 1972.
14.
Palmieri GMA, Nordquist RE, Omenn GS. Content and intracellular localization of parathyroid hormone in human
tumors. J Clin Invest 1972; 51:72a.
15.
Omenn GS, Figley MM, Heinrichs WL. Radiographic intra-uterine diagnosis for the TAR syndrome (thrombocytopenia
with absent radii). Amer J Hum Genet 1972; 24:31a.
16.
Schrott HG, Karp L, Omenn GS. Prenatal diagnosis of myotonic dystrophy (Dm). Amer J Hum Genet 1972; 24:32a.
17.
Omenn GS. Phosphoglycerate mutase: isoenzyme marker for tissue differentiation in man. XIII Intl Cong Genet,
Berkeley, August 20-29, 1973.
18.
Omenn GS. Eco-genetics: Host variability in health effects of environmental agents. Intl Symp on Recent Advances in the
Assessment of the Health Effects of Environmental Pollution, Paris, June 24-28, 1974.
19.
Omenn GS, Cheung S. Pharmacogenetic analysis of monoamine oxidase activity in human and macaque brain. 7th Ann
Mtg Amer Soc Neurochemistry, Vancouver, BC, March 14-19, 1976.
20.
Omenn GS, Smith L. Platelet uptake of neurotransmitters: model for neuronal reuptake mechanisms. 6th Ann Mtg Behav
Genet Assn, Boulder, CO, June 17-19, 1976.
21.
Omenn GS, Hall JG, Graham CB, Karp LE. The use of radiographic visualization for prenatal diagnosis. 1976 Birth
Defects Conf, Vancouver, BC, June 23-25, 1976.
22.
Omenn GS, Farquhar MN. Gene expression in human brain: DNA/RNA hybridization studies. V Intl Cong Hum Genet,
Mexico City, October 10-15, 1976.
23.
Omenn GS, Smith L. A common uptake mechanism for serotonin and dopamine in human platelets. Clin Res 1977;
25:324a.
24.
Larson EB, Omenn GS, Loop JW, Margolis MT. Impact of new technology: computed tomography of the brain. Clin Res
1977; 25:329a.
25.
Omenn GS, Weber BA. Dyslexia: search for phenotypic and genetic heterogeneity. Ann Mtg Behavior Genet Assn,
Louisville, KY, April 28-30, 1977.
26.
Davenport SLH, Omenn GS. The heterogeneity of Usher syndrome. 5th Intl Conf Birth Defects, Montreal, August, 1977.
27.
Luthy DA, Hall JG, Omenn GS, Graham CB. Prenatal diagnosis by the use of radiographic visualization. 5th Intl Conf
Birth Defects, Montreal, August, 1977.
28. Omenn GS, Hall JG, Hansen KD. Genetic counseling: the search for an adopted child - legal and ethical
considerations. 5th Intl Conf Birth Defects, Montreal, August, 1977.
29.
Davenport SLH, Omenn GS, Kalina RE. A kindred with choroideremia and anhidrotic ectodermal dysplasia. Amer J Hum
Genet 1977; 29:536a.
30.
Smith LT, Hanson DR, Omenn GS. Comparisons of serotonin uptake by blood platelets and brain synaptosomes. Amer J
Hum Genet 1977; 29:101a.
31.
Larson EB, Omenn GS, Loop JW, Margolis MT. Impact of computed tomography on patient care-relevant information for
efficient use of health care resources. Ann Mtng Robert Wood Johnson Clinical Scholars Program, October, 1977.
32.
Omenn GS, Smith LT, Hanson DR. Platelet and synaptosome uptake of serotonin differ in vitro. Trans Amer Soc
Neurochem 1978; 9:197.
33.
Larson EB, Omenn GS, Lewis H. Diagnostic evaluation of headache: impact of computed tomography and cost
effectiveness. Clin Res 1979; 27:279a.
34.
Hrubec Z, Omenn GS. Evidence of predisposition to alcoholic cirrhosis and psychosis: twin concordances for alcoholism
and its biological end-points by zygosity among male veterans. Amer J Hum Genet 1980; 32:112a.
35.
Omenn GS. From pharmacogenetics to ecogenetics. 6th Intl Cong Hum Genet, Jerusalem, Israel, September, 1981.
36.
Omenn GS. Characterization of risk of potential human mutagens and carcinogens: basis for prioritization of regulatory
action. 3rd Intl Conf Environmental Mutagens, Tokyo, September 1981, abst TP2-2, p. 25.
37.
Omenn GS. Eco-s: ally-determined differences in susceptibility to environmental mutagens and carcinogens. 3rd Intl Conf
Environmental Mutagens, Tokyo, September, 1981, abst 1F04, p. 49.
38.
Omenn GS. University/industry research linkages: arrangements between faculty members and their universities. AAAS,
Washington, DC, January, 1982.
39.
Lave LB, Omenn GS, Dranoff G, Heffernan K. Analysis of the cost-effectiveness of tier testing for potential carcinogens.
1st World Cong on Toxicology & Environmental Health, Washington, DC, May, 1982.
40.
Omenn GS. Environmental risk assessment: relation to mutagenesis, teratogenesis, and reproductive events. 1st World
Cong on Toxicology and Environmental Health, Washington, DC, May, 1982.
41.
Omenn GS. Scientific challenges in the implementation of the Clean Air Act: qualitative and quantitative characterization
of risks of health effects. Ann Mtng National Air Pollution Control Association, New Orleans, June, 1982, p. 82-95.
42.
Omenn GS, Faustman-Watts E. Teaching risk assessment for environmental health hazards to a multi-disciplinary
graduate student audience. 112th Ann Mtg Amer Pub Hlth Assn, November, 1984, p. 182.
43.
Omenn GS. On biomedical research and health care costs. Invited commentary. Issues in Science and Technology, Winter
1985; 1:11-12.
44.
Goodman GE, Omenn GS, Feigl P, Kleinman GD, Lund B, Thomas DB, Henderson MM, Prentice R. Chemoprevention
of lung cancer with retinoids/beta-carotene. Second Intl Conf on the Modulation and Mediation of Cancer by Vitamins,
February 10-13, 1985.
45.
Childs MD, Dorsett C, Failor A, Roidt L, Omenn G. Effect of shellfish consumption on plasma lipids and cholesterol
absorption in normolipidemic man. Fed Proc 1985; 44:1142.
46.
Omenn GS, Faustman-Watts E. An overview of the risk assessment/risk management process. Teratology 1985; 31:34a.
47.
Omenn GS. Preventing low birth weight. West J Med 1985; 143:5:657-658.
48.
Thompson B, Omenn G, Sexton M, Breitenstein B, Hessol N, Curry S, Michnich M, Peterson A. Worksite smoking
cessation: a test of two programs. Adv Cancer Control IV, Washington, DC, April, 1986.
49.
Omenn GS. Activation and inactivation of carcinogens: variability and environmental influence. Intl Symposium
Biochemical and Cellular Indices of Human Toxicity in Occupational and Environmental Medicine, Milan, Italy, May,
1986.
50.
Furlong CE, Richter RJ, Seidel S, Motulsky AG, Omenn GS, Murphy SD, Costa LG. Organophosphate toxicity and the
paraoxonase polymorphism. Amer J Hum Genet, 39:A11, September, 1986.
51.
Omenn GS. The role of differences in human susceptibility to pesticides. NATO Advanced Study Institute on Toxicology
of Pesticides, October 6-15, 1986, Riva del Garda, Italy.
52.
Costa LG, Richter RJ, Murphy SD, Omenn GS, Motulsky AG, Furlong CE. Species differences in serum paraoxonase
correlate with sensitivity to paraoxon toxicity. NATO Advanced Study Institute on Toxicology of Pesticides, October 615, 1986, Riva del Garda, Italy.
53.
Omenn GS, Goodman G, Rosenstock L, Barnhart S, Lund B, Thornquist M, Feigl P. Cancer chemoprevention in high-risk
populations with vitamin A and beta-carotene. 2nd Intl Conf on Anticarcinogenesis and Radiation Protection, March 8-12,
1987, Gaithersburg, MD.
54.
Omenn GS, Goodman G, Rosenstock L, Barnhart S, Lund B, Kleinman G, Feigl P. Chemoprevention of lung cancer in
asbestos-exposed men. PREVENTION 87, April 9-12, 1987, Atlanta, GA.
55.
Omenn GS, Thompson B, Hessol N, Breitenstein B, Curry S, Sexton M, Michnich M, Peterson A. Smoking cessation and
relapse prevention services in a large worksite population. PREVENTION 87, April 9-12, 1987, Atlanta, GA.
56.
Omenn GS, Goodman G, Rosenstock L, Barnhart S, Feigl P. Chemoprevention of lung cancer with retinol and betacarotene in asbestos-exposed men. Amer Occ Med Assn, April 25 to May 2, 1987, Philadelphia, PA.
57.
Omenn GS. Overview on risk assessment for occupational chemical exposures. Amer Occ Med Assn, April 25 to May 2,
1987, Philadelphia, PA.
58.
Omenn GS, Goodman G, Rosenstock L, Barnhart S, Feigl P. Chemoprevention of lung cancer in asbestos-exposed men.
22nd Intl Cong on Occ Health, September 27 to October 2, 1987, Sydney, Australia.
59.
Barnhart S, Rosenstock L, Feigl P. Thornquist M, Goodman G, Omenn G. Does smoking behavior affect fibrosis among
an asbestos-exposed cohort? 22nd Intl Cong on Occ Health, Sept 27 to Oct 2, 1987, Sydney, Australia.
60.
Rosenstock L, Barnhart S, Omenn G, Hudson L. Limitations of applying ILO profusion categories in case identification
among asbestos-exposed cohorts. 22nd Intl Cong on Occ Health, September 27 to October 2, 1987, Sydney, Australia.
61.
Omenn GS, Goodman GE, Rosenstock L, Barnhart S, Feigl P, Thornquist M. Chemoprevention of lung cancer with beta-
carotene and retinol in persons at high risk due to asbestos occupational exposures and/or cigarette smoking, a doubleblind randomized trial. International Symposium/Workshop on Biological Interaction of Inhaled Mineral Fibers and
Cigarette Smoke, April 10-14, 1988, Seattle, WA.
62.
Parcel GS, Labarthe DR, Williams OD, Omenn GS, Buchner DM, Raymond JS, Solomon SL. Centers for Research and
Demonstration in Health Promotion and Disease Prevention. PREVENTION 88: Prevention and Primary Care, April 1417, 1988, Atlanta, GA.
63.
Omenn GS, Beery B, Buchner D, Carter W, Day RW, Perrin E, Wagner E. Center for Health Promotion in Healthy Older
Adults. PREVENTION 88, April 14-17, 1988, Atlanta, GA.
64.
Omenn GS. The role of genetics in occupational medicine: identification of highly susceptible workers in pre-employment
and periodic examinations. 6th Israel Medical Week, 14th World Congress of the Israel Medical Assn., May 15, 1988.
65.
Furlong CE, Richter RJ, Seidel S, Costa G, McDonald BE, Murphy SD, Omenn GS, Motulsky AG. Hydrolysis of
paraoxon and chlorpyrifos oxon by human, rabbit and rat serum paraoxonase/arylesterase. Amer J Hum Genet 1988; 43
Suppl) 3:A6.
66.
Omenn GS. Ecogenetics of chemical carcinogens. UCLA Symposia on Molecular & Cellular Biology, 18th Annual
Meeting. J Cellular Biochemistry 1989; (Suppl 13D):4.
67.
Omenn GS. Eco-s: Testing for predispositions to health impairments from occupational or environmental exposures to
chemicals. PREVENTION 89, April 13-16, 1989, Atlanta, GA.
68.
Boatman ES, Covert D, Kalman D, Luchtel D and Omenn GS. Characterization of dusts collected during the machining of
epoxy-reinforced fibrous materials. In: Wehner AP, editor. Biological Interaction of Inhaled Mineral Fibers and Cigarette
Smoke. International Symposium/Workshop. Seattle, WA: Battelle Press; 1989. p. 441-442.
69.
Thornquist M, Omenn GS. Participation and compliance among older men and women recruited to the beta-Carotene and
Retinol Efficacy Trial (CARET) to prevent lung cancer in heavy smokers and in asbestos-exposed workers. Conference on
Participation of the Elderly in Health Programs, UW, Seattle, WA. Nov 15, 1989.
70.
Wagner EH, Passmore M, Scholes D, Grothaus L and Omenn GS. A randomized trial to prevent disability in the well
elderly. Proceedings, PREVENTION 90: Assuring the Public's Health, April 19-22, 1990; p.37.
71.
Kosorok R, Omenn GS, Diehr P, Koepsell TD and Patrick DL. Estimates of the relationship between the number of
restricted activity days and multiple chronic conditions for people over the age of 65 based on the 1984 Supplement on
Aging of the National Health Interview Survey. Presented at PREVENTION 90: Assuring the Public's Health,
April 19-22, 1990; p.36.
72.
Omenn GS and Bourquin AW. Research and development priorities for environmental biotechnology and the role of intersectoral cooperation. Presented at the European Environmental Research Organization (EERO) Environmental
Biotechnology Symposium, April 23-27, 1990, Braunschweig, Germany.
73.
Goodman GE, Omenn GS. Seattle lung cancer chemoprevention trial: CARET: beta-carotene and retinol efficacy trial.
Proceedings, Amer Soc Clin Oncology, March, 1990; 9:233.
74.
Omenn GS, Anderson KW, Kronmal RA, Vlietstra RE. The temporal pattern of reduction of mortality risk after smoking
cessation. Presented at PREVENTION 90: Assuring the Public's Health, April 19-22, 1990; p.25.
75.
Grizzle JE, Omenn GS, Thornquist M, Rosenstock L, Barnhart S, Cone J, Cullen M, Goodman G, Keogh J, Valanis B.
Design of the beta-Carotene and Retinol Efficacy Trial (CARET) for chemoprevention of cancer in populations at high
risk: heavy smokers and asbestos-exposed workers. 15th International Cancer Congress. Hamburg, Germany.
Aug 16-22, 1990.
76.
Lave LB, Omenn GS, Rosenkranz H, Ennever F. Economic considerations in screen selection and use. Amer Coll Tox
Annual Meeting, October 29, 1990.
76.
Omenn GS. Conference on participation of the elderly in health programs. Amer J Health Promotion Jan/Feb 1990;
p. 242.
78.
Anderson K, Wilson B, Omenn GS. Endpoint review process in a multicenter lung cancer chemoprevention trial. Amer
Soc Preventive Oncology 15th Ann Mtg, April 9-12, 1991.
79.
Omenn GS. The carotene and retinol efficacy trial (CARET): a case study for the symposium on strategies for cancer
prevention trials. Amer Soc Preventive Oncology 15th Ann Mtg, April 9-12, 1991.
80.
Omenn GS. Ethical issues in conducting cancer prevention trials. Amer Soc Preventive Oncology 15th Ann Mtg, April 912, 1991.
81.
Omenn GS. Eco-s: The role of variation in susceptibility to environmental agents. Soc Epidemiologic Research, June,
1991.
82.
Faustman EM, Streissguth AP, Stevenson LM, Omenn GS, Yoshida A. Maternal and fetal alcohol metabolizing genotypes
in fetal alcohol syndrome. Teratology Soc Mtg, 1991.
83.
Brodkin CA, Barnhart S, Anderson G, Checkoway H, Omenn GS, Rosenstock L. Correlation between respiratory
symptoms and pulmonary function in asbestos-exposed workers: a longitudinal analysis. The 9th International Symposium
on Epidemiology in Occupational Health. Cincinnati, Ohio, 1992.
84.
Brodkin CA, Barnhart S, Anderson G, Checkoway H, Omenn G, Rosenstock L. Correlation between respiratory symptoms
and pulmonary function in asbestos-exposed workers: a cross-sectional and longitudinal analysis. Am Rev Respir Dis
145:A197, 1992.
85.
Omenn GS. Overview: Future directions for hazardous waste research. AAAS Annual Meeting, Feb 6-11, 1992; p.128.
86.
Moon T, Labarthe D, Cross A, Wood DW, Omenn GS. Making prevention a practical reality. PREVENTION 92:
Linking Science, Policy and Practice, March 21-24, 1992; p.22.
87.
Wagner EH, Karlen P, Martin M, Omenn GS, Buchner DM. Developing an HMO as a laboratory for preventive research
in older adults. PREVENTION 92: Linking Science, Policy and Practice, March 21-24, 1992; p.26.
88.
Carter W, Omenn GS, Crump C, Koszma C, Williams OD, Grunbaum J et al. Worksite health promotion in federal
agencies. PREVENTION 92: Linking Science, Policy and Practice, March 21-24, 1992; p.36.
89.
Omenn GS. Molecular epidemiology and cancer risk assessment. The Seventh Aspen Cancer Conference Workshop-Mechanisms of Toxicity and Carcinogenesis, July 18-22, 1992. Toxicologic pathology 1992; 20:667-668.
90.
Hoover JJ, Tapp JW, Omenn GS. Northwest Center for Public Health Practice: a university resource for healthy
communities. APHA Ann Mtg, Nov 8-12, 1992; p.221.
91.
Omenn GS. The role of scientists in the courtroom: The scientist's perspective. AAAS Annual Meeting, Feb. 11-16, 1993;
p.126.
92.
Goodman GE, Omenn GS, Lund B, Thornquist M, Metch B, Gylys-Colwell I. Long term evaluation of side effects of
beta-carotene and retinol: smoker's pilot to the carotene and retinol efficacy trial (CARET). American Society of
Preventive Oncology, Mar 20-23, 1993, Tucson, AZ.
93.
Omenn GS, Katz A, Madden C, Berkowitz B. Prevention and public health in health system reform: the state of
Washington proposal. PREVENTION 93: Leadership for Prevention in Health Care Reform, April 17-20, 1993; p.30.
94.
Omenn GS, Cain KC, Ye Z, Kronmal RA. Total serum cholesterol levels and mortality risk as a function of age: a report
based on the Framingham data. PREVENTION 93: Leadership for Prevention in Health Care Reform, April 17-20, 1993;
p.43.
95.
Carter W, Omenn GS, Towns B, Breslow L, Benedict S, Cross A, Grunbaum J, Labarthe DR, Vuturo T, Landis M, Wood
DW. Provide leadership to help federal agencies develop effective worksite health promotion programs. PREVENTION
93: Leadership for Prevention in Health Care Reform, April 17-20, 1993; p.48.
96.
Omenn GS. CARET Co-investigators and staff. The Carotene and Retinol Efficacy Trial (CARET) for chemoprevention
of lung cancer in high-risk populations. 4th International Conference on Anti-Carcinogenesis and Radiation Protection,
Baltimore, MD. Apr 18-23, 1993.
97.
Omenn GS and CARET Co-investigators. CARET: The -Carotene and Retinol Efficacy Trial for chemoprevention of
lung cancer in high-risk populations:smokers and asbestos-exposed workers. Aspen, Colorado. July 17-22, 1993.
98.
Omenn GS. How molecular investigations can improve the way we determine and explain risk. Symposium on Cell
Signaling and the Molecular Stress Response, September 23-26, 1993, Lake Placid, NY.
99.
Omenn GS and CARET Co-Investigators. CARET: the beta-carotene and retinol efficacy trial for chemoprevention of
lung cancer in high-risk populations: smokers and asbestos-exposed workers. Toxicologic Pathology 21; 631-632, 1994.
100.
Omenn GS. CARET, the -Carotene and Retinol Efficacy Trial for chemoprevention of lung cancer in high-risk
populations: progress and issues. ILSI, January 23-26, 1994, Nassau, Bahamas.
101.
Omenn GS. Biotechnology in health care. AAAS Annual Meeting, Feb. 18-23, 1994; p.62.
102.
Anderson K, Guarnero D, Powell C, Boyle P, Omenn GS. CARET certification: a process to ensure proficient staff and
consistent performance in a large, multi-site chemoprevention study. American Society of Preventive Oncology, March
6-9, 1994, Bethesda, MD.
103.
Goodman G, Gylys-Colwell I, Anderson G, Kestin M, Omenn GS and CARET co-investigators. Association between
food frequency questionnaire estimates and serum concentrations of tocopherol among participants in the CARET lung cancer chemoprevention trial. 15th Annual Meeting, Society for
Clinical Trials, May 8-11, 1994, Houston, TX.
104.
Novais B J, Wagner E, Buchner D, LaCroix A, Patrick D. Beresford S, Omenn GS. compliance with an exercise program
in a senior center: a randomized trial. American Geriatrics Society, May 20, 1994, Los Angeles, CA.
105.
Omenn GS. The mandate and status of the President's Commission on Risk Assessment and Risk Management. ILSI,
January, 1995, Cancun, Mexico; p.37-38.
106.
Williams J, Meyskens F, DeJohn J, Zolkower J, Thornquist M, Omenn G, Goodman G, Metch B, Valanis B, Glass A,
Balmes J, Keogh J, Cullen M. Retention in ongoing CARET cancer prevention study is affected by related study reports.
19th Annual Meeting, American Society of Preventive Oncology, Houston, TX, March 8-11, 1995.
107.
Omenn GS. Reaping new findings from existing datasets. CDC Annual Prevention Center Directors Meeting. Atlanta,
February, 1994.
108.
Thornquist MD, Omenn GS, Goodman GE, Grizzle JE, and CARET Co-investigators. Maintenance of a
chemoprevention trial of lung cancer (CARET)after the conclusion of recruitment. 16th International Cancer congress,
New Dehli, India. October 30-November 5, 1994.
109.
Blackmon BD, Stover B, Brodkin CA, Omenn GS, Balmes J, Barnhart S. Utility of basilar crackles and clubbing as
diagnostic criteria for asbestosis in an asbestos exposed cohort. Am J Respir & Crit Care Med 151:A709, 1995.
110.
McCullough J, Brodkin CA, Stover B, Hammar S, Checkoway H, Balmes J, Omenn G, Barnhart S. Lobe of origin and
tumor histology as indicators of asbestos related lung cancer. Am J Respir & Crit Care Med 151:A710, 1995.
111.
Balmes J, Keogh J, Brodkin CA, Williams J, Stover B, Metch B, Omenn G, Barnhart S. Does beta-carotene protect
against loss of ventilatory function? Am J Respir & Crit Care Med 151:A96, 1995.
112.
Thornquist M, Goodman G, Omenn G, and CARET Co-investigators. Effectiveness of a placebo run-in period in
increasing the power of a chemoprevention trial, CARET. Controlled Clin Trials 16(3S:)63S, 1995.
113.
Omenn GS. Cancer risk factors: occupational, lifestyle, and environmental. NCI Conference: Prospects for
Chemoprevention in Cohorts with Cancer Risk markers, Oct., 1995.
114.
Omenn GS. Making science count in risk management decisions. Environmental and Molecular Mutagenesis 1996;
27(Suppl 27):52.
115.
Omenn GS. Chemoprevention and nutrition. Mechanisms of Toxicity and Carcinogenesis. Omenn GS. Progress in
science-based risk assessment and risk management. Technology 1994; 331A:21-27.
116.
Charnley G, Omenn GS. Improving risk assessment and risk management in federal regulatory programs. Society of
Toxicology, Anaheim, CA, March 1996.
117.
Omenn GS. Screening for predispositions to common diseases. Proceedings, Cambridge Symposium on Molecular
Approaches to the Treatment of Disease. Lake Tahoe, NV, Oct. 26, 1996; p.8.
118.
Kessler A, Zotter DM, Omenn GS. Appropriate roles for judicial review of regulatory actions by agencies regulating
health, safety, and the environment. Annual Meeting, American Public Health Association, New York, November 1996;
Abstracts 2232, p.284.
119.
Goldstein B, Omenn GS. Giving risk-based environmental decisions a public-health context. Annual Meeting, American
Public Health Association, New York, November 1996; Abstracts 2232, p.284.
120.
Omenn GS, Charnley G. Bright lines: helpful to decision-makers and communities, or overly simplistic? Annual
Meeting, American Public Health Association, New York, November 1996; Abstracts 2232, p.284.
121.
Omenn GS, Chiu PY, Goldman LR, Stratton JW, Roe D, Sigman DD. Science-based risk management in regulatory
agencies: assessing Risk Commission recommendations. AAAS Annual Meeting, Feb. 14-16, 1997; p.A-60.
122.
Omenn GS. Contributions of behavioral and social science to public health. AAAS Annual Meeting, Feb. 14-16, 1997;
p.A-47.
123.
Omenn GS. Risk assessment, risk management, and holistic thinking. AAAS Annual Meeting, Feb. 14-16, 1997;
p.A-59.
124.
Omenn GS. Risk Commission recommendations of special interest to toxicologists and risk assessors. Society of
Toxicology Annual Meeting, March 1997. The Toxicologist 1997; 36:51-52.
125.
Boyle MM, Edelstein C, Gonzalez-White M, Thornquist M, Tietje K, Omenn GS. Human subjects review in long-term
prevention trials: recommendations from the CARET experience. Controlled Clinical Trials 1997; 18:170S.
126.
Omenn GS. New approaches to carcinogen assessment in the context of risk assessment. Omenn GS. Progress in
science-based risk assessment and risk management. Technology 1994; 331A:21-27. The 12th Aspen Cancer Biology
Conference: Mechanisms of Toxicity and Carcinogenesis. (Extended Abstract in press in Toxicologic Pathology)
127.
Omenn GS. The messenger under attack: intimidation of researchers by special interest groups/responsibilities of
universities and journals. Proc. AAAS 150th Ann Mtg, Philadelphia, Feb. 14, 1998, Pp. A68-69.
128.
Omenn GS. Screening for genetic predispositions. Proc. ACP Annual Meeting, San Diego, April 2-5, 1998, p. 41.
129. Omenn GS. Genetics and public health: keynote for the CDC conference on translating advances in human genetics
into disease prevention and health promotion. CDC 1st Annual Conf. on Genetics and Public Health, Atlanta,
May 13-15, 1998, p.39.
130.
Mosca L, Tarshis T, Rhodes K, Rubenfire M, Omenn GS: Evidence that vitamin E in food, not supplements,
protects low-density lipoprotein (LDL) from oxidation in postmenopausal women. Circulation 1999 (8): 1123.
131.
Omenn GS: Use of the precautionary principle is a stimulus to improve the scientific base for environmental risk
management decisions. Proc. AAAS Annual Meeting, Washington DC, Feb. 17-22, 2000, p. A65.
132. Omenn GS: Scientific due process. Issues in Science and Technology, Fall 2000, 17:1, p. 6-7.
133. Omenn GS: Challenges of risk characterization for perfluorooctanesulfonate (PFOS): a persistent, pervasive
fluorochemical. Toxicological Sciences, 2002, 66;1S, p. 112.
134. Omenn GS: Biomarkers and Surrogate Endpoints in Chemoprevention and Early Detection of Cancer. AACR 94 th
Annual Meeting, Washington, DC, July 11-13, 2003.
135. Omenn GS: HUPO Plasma Proteome Project Pilot Phase; reference specimens, technology platform comparisons
and standardized data submissions and analysis. Proteomic Forum, Munich, Germany, September 2003.
136.
Wang H, Misek D, Galchev V, Duffner U, Ferrara J, Omenn G, Hanash S: Highly sensitive and efficient, multidimensional analysis of intact proteins to decipher the human serum proteome in graft-versus-host disease. HUPO World
Congress, Montreal, Canada, October 2003.
137. Omenn, GS: Assessment of the impact of the 1983 Red Book. SRA Annual Meeting, Baltimore, Maryland,
February 2004.
138.
McCusker M, Omenn GS, Wikler D. Genomics and prevention: past, present and future. Proc Preventive Medicine
(ACPM), Orlando, FL, February 18-22, 2004, pp. 49-50.
139. Omenn GS: The HUPO Plasma Proteome Project Pilot Phase; reference specimens, technology platform
comparisons and standardized data analysis. AACR 95th Annual Meeting, Orlando, Florida, March 27-31, 2004.
140. Creighton C, Webb C, Misek M, Giordano T, Omenn G, Hanash S: Integration of genomic data from A549
xenograft tumors with protein-protein interaction information for functional network analysis. AACR 95th Annual
Meeting, Orlando, Florida, March 2004.
141.
Qiu J, Madoz-Gurpide J, Kuick R, Misek D, Michailidis G, Haab B, Brenner D, Omenn G, Hanash S: Profiling the
humoral response in lung cancer using natural protein microarrays. AACR, Orlando, Florida, March 2004.
142. Omenn, GS. State of the Art: Carotenoids and Retinoids as Cancer Prevention Interventions in Humans.
CHS Translational Cancer Prevention Workshop, Haifa, Israel, May 4-6, 2004.
143.
Omenn, GS. Constructing a knowledge base for the Human Plasma Proteome. AACR Advances in Proteomics in
Cancer Research conference, Key Biscayne, Florida, October, 2004.
144.
Omenn, GS. Adverse effects in chemoprevention trials: evidence of adverse interaction between asbestos exposure
and the beta-carotene/retinyl palmitate intervention in CARET. AACR Frontiers in Cancer Research conference,
Seattle, Washington, October 16-20, 2004.
145. Omenn, GS. Chemoprevention of Lung Cancer: Lessons from CARET, the Beta-Carotene and Retinol Efficacy
Trial. CHS International Educational Cancer Prevention Conference, Dead Sea, Israel, May 6-8, 2004.
146.
Omenn, GS. Constructing a knowledge base for the Human Plasma Proteome. AACR Advances in Proteomics in
Cancer Research conference, Key Biscayne, Florida, October, 2004.
147.
Omenn, GS, Barnett MJ, Balmes JR, Cartmel B, Brodkin CA, Barnhart S, Rosenstock L, Goodman GE,
Hammar SP. Adverse effects in chemoprevention trials: evidence of adverse interaction between asbestos exposure and the
beta-carotene/retinyl palmitate intervention in CARET. AACR Third Annual Conference on Frontiers in Cancer Prevention
Research, Seattle, Washington, October 16-20, 2004, abstract C-116.
148.
Zhang Q, Misek D, Kuick R, Wang H, Galchev V, Tra J, Pisano M, Strahler J, Andrews P, Omenn GS, Hanash SM. Intact
Protein Analysis System (IPAS) based on Quantitative Profiling of Plasma for Lung Cancer Biomarkers.
HUPO 3rd Annual World Congress, Beijing, 25-27 October, 2005, abstract 3.5, Congress Manual, p. 113.
149. Adamski M, Taylor C, Martens L, Apweiler R, States DJ, Simpsonn R, Omenn GS, Hermjakob H. Data acquisition
and integration in the pilot phase of the HUPO Plasma Proteome Project. HUPO 3rd Annual World Congress,
Beijing, 25-27 October, 2005, abstract 19.1, Mol Cell Proteomics 2004; 3 (10), Suppl: S213.
150.
151.
Omenn GS. The HUPO Plasma Proteome Project. HUPO 3rd Annual World Congress, Beijing, 25-27 October,
2005, abstract 20.2, Mol Cell Proteomics 2004; 3 (10), Suppl: S225.
Omenn GS, Adamski M, States D, Chan D, Simpson R, Hermjakob H, and HUPO PPP Investigators. HUPO 3
Annual World Congress, Beijing, 25-27 October, 2005, abstract 20.3, Mol Cell Proteomics 2004; 3 (10),
Suppl: S225.
Updated November 2004